



**COLLEGE OF HEALTH SCIENCES  
SCHOOL OF NURSING AND MIDWIFERY  
DEPARTMENT OF NURSING**

**AWARENESS OF PROSTATE CANCER AND ITS  
ASSOCIATED FACTORS AMONG MALE PATIENTS  
ATTENDING IN UROLOGY UNIT AT TIKUR ANBESSA  
SPECIALIZED HOSPITAL, ADDIS ABABA ETHIOPIA, 2021**

**By: Tilaye Gebru (BSc)**

**A Thesis to Be Submitted to The Addis Ababa University  
School of Graduate Studies, College of Health Sciences, The  
School of Nursing and Midwifery, Department of Nursing for  
Partial Fulfilment of The Requirements for A Master of  
Sciences in Oncology Nursing.**

**June 2021**

**Addis Ababa, Ethiopia**



**COLLEGE OF HEALTH SCIENCES  
SCHOOL OF NURSING AND MIDWIFERY  
DEPARTMENT OF NURSING**

**AWARENESS OF PROSTATE CANCER AND ITS  
ASSOCIATED FACTORS AMONG MALE PATIENTS  
ATTENDING IN UROLOGY UNIT AT TIKUR ANBESSA  
SPECIALIZED HOSPITAL, ADDIS ABABA ETHIOPIA, 2021**

**ADVISORS: -**

- 1. HUSSEN MEKONNEN (MPH, PHD)**
- 2. NEGALIGN GETAHUN (BSc, MSc, LECTURER)**
- 3. DR. MESSAY MEKONNEN (UROLOGIST)**

**A Thesis to Be Submitted to The Addis Ababa University School of Graduate Studies, College of Health Sciences, The School of Nursing and Midwifery, Department of Nursing for Partial Fulfilment of The Requirements for A Master of Sciences in Oncology Nursing.**

**June 2021**

**Addis Ababa, Ethiopia**

**APPROVAL SHEET**  
**APPROVAL BY THE REVIEW BOARD**

This thesis by **Tilaye Gebru** is accepted in its presence by the board of examiners to meet the thesis requirements for a master's degree in clinical oncology nursing.

**INTERNAL EXAMINER**

<b>Mr. Yosef Tsige</b>	Assistance proff.	_____	June 2021
------------------------	-------------------	-------	-----------

**ADVISOR (s)**

<b>Dr. Hussen Mekonnen</b>	(MPH, PhD)	_____	June 2021
----------------------------	------------	-------	-----------

<b>Mr. Negalign Getahun</b>	(MSc. Lecturer)	_____	June 2021
-----------------------------	-----------------	-------	-----------

**DEPARTMENT HEAD**

<b>Mr. Niguse Tadele</b>	Assistance proff.	_____	June 2021
--------------------------	-------------------	-------	-----------

## **DEDICATION**

To my advisor, Dr. Ayinalem Abreha. He was a well-known oncologist and director of the AAU Cancer Centre who devoted his life to the care of cancer patients at TASH, where he worked for several years. He will be recognized for his compassion, humility, and valued contribution to my life.

## STATEMENT OF DECLARATION

This study is our work, as shown by our signature below. In the planning, data collection, analysis, and completion of this thesis, I followed all ethical guidelines. The thesis acknowledges and cites all literature materials. I certify that all references used in this document have been cited and referenced. During the writing of this thesis, every attempt was made to prevent plagiarism.

<b>Tilaye Gebru</b>	(BSc)	_____	June 2021
<b>Hussen Mekonnen</b>	(MPH, Ph.D.)	_____	June 2021
<b>Negalign Getahun</b>	(MSc. Lecturer)	_____	June 2021

## **ACKNOWLEDGMENTS**

First and foremost, I would like to thank the School of Nursing and midwifery, College of Health Sciences, Addis Ababa University for allowing me to pursue my MSc study and to conduct this research. I duly acknowledge Haramaya University for providing me with the sponsor to attend my MSc study.

I wish to express my heartfelt and special thanks to my advisor (s), Hussen Mekonnen (Ph.D., Assistant Professor of Public Health), Dr. Messay Makonnen (Urologist), Mr. Negalign Getahun, (MSc, Lecture) for dedicating their valuable time to offer insightful comments and guidance on the overall goodness of this study.

I want to thank Tikur Anbessa Specialized Hospital, the Oncology and Urology Unit for their cooperation in providing the necessary information on the study areas and subjects.

Last but not least, I would like to thank my friends and my family who courageously endure during my time away, as pursued the end of this Master's degree program.

Above all, I want to thank the Almighty God for giving me strength and stamina.

## **ABBREVIATIONS AND ACRONYMS**

AAU	Addis Ababa University
ACS	American Cancer Society
BPH	Benign Prostate Hyperplasia
DRE	Digital Rectal Examination
ETB	Ethiopian Birr
FMOH	Federal Ministry of Health
IARC	International Agency of Research for Cancer
P CA	Prostate Cancer
PI	Principal Investigator
PSA	Prostate Specific Antigen
SSA	Sub Saharan Africa
TASH	Tikur Anbessa Specialized Hospital

## **TABLE OF CONTENTS**

APPROVAL SHEET	ii
DEDICATION	iii
STATEMENT OF DECLARATION	iv
ACKNOWLEDGMENTS	v
ABBREVIATIONS AND ACRONYMS	vi
LIST OF TABLES	ix
LIST OF FIGURES	x
LIST OF APPENDIX TABLES	xi
ABSTRACT	xii
1.INTRODUCTION	1
1.1. Background	1
1.2. Statement of problem	3
2.LITERATURE REVIEW	5
2.1. Introduction	5
2.2. Awareness of prostate cancer	8
2.3. Associated factors with Awareness of prostate cancer	10
2.4. Conceptual Framework	14
JUSTIFICATION OF THE STUDY	15
SIGNIFICANCE OF THE STUDY	16
3.OBJECTIVES OF THE STUDY	17
3.1. General Objectives	17
3.2. Specific Objective	17
4.MATERIALS AND METHODS	18
4.1. Study area and study period	18
4.2. Study Design	18
4.3. Population	18
4.3.1. Source Population	18
4.3.2. Study Population	18



4.4. Inclusion and exclusion criteria	18
4.5. Sample Size Determination	19
4.6. Sampling procedure	20
4.7. Study Variables	20
4.8. Operational Definition	21
4.9. Data collection tool and Data collection procedure	22
4.10. Data Quality Management	22
4.11. Data processing and Analysis	23
4.12. Ethical Consideration	24
4.13. Dissemination Study Results	24
5.RESULTS	25
5.1. Socio-demographic characteristics of the respondents	25
5.2. The patient-related factors of the respondents	27
5.3. Awareness of prostate cancer and its components score	28
5.4. Associated factors with the awareness of prostate cancer	33
6.DISCUSSION	35
7.STRENGTH AND LIMITATION OF THE STUDY	38
8.CONCLUSION AND RECOMMENDATIONS	39
8.1. Conclusion	39
8.2. Recommendations	40
9.REFERENCE	41
10.APPENDIX	48
APPENDIX- A: INFORMATION SHEET	48
APPENDIX- B: CONSENT FORM	50
APPENDIX -C: QUESTIONNAIRE (ENGLISH VERSION)	51
APPENDIX -D: QUESTIONNAIRE AMHARIC VERSION	57
APPENDIX -E: LEAFLET OF AWARENESS	62

## LIST OF TABLES

Table 1 Socio-demographic characteristics of respondents in TASH, Addis Ababa, Ethiopia, 2021 [n=241]	26
Table 2: The patient-related factors of the Respondents in TASH, Addis Ababa, Ethiopia, 2021 [n=241]	27
Table 3 Distribution of study participants on the awareness of prostate cancer in TASH, Addis Ababa, Ethiopia, 2021 [n=241].	29
Table 4: Predictors of awareness of prostate cancer based on the simple linear regression analysis model, in TASH, Addis Ababa, Ethiopia, 2021 [n=241].	31
Table 5: Predictors of awareness of prostate cancer based on the multiple linear regression analysis models, in TASH, Addis Ababa, Ethiopia, 2021 [n=241].	34

## **LIST OF FIGURES**

- Figure 1: The conceptual framework of awareness status of prostate cancer and associated factors among patients attending in Urology at Tikur Anbessa Specialized Hospital, Addis Ababa, Ethiopia, 2021 14
- Figure 2: Distribution of the proportion score of prostate cancer awareness and its' components from the total expected score among male patients in the Urology unit at TASH, Addis Ababa, Ethiopia, in 2021. 30

## LIST OF APPENDIX TABLES

Table 6. 1 PART I: The question has to do with background information. ....	51
Table 6. 2 PART II: The questionnaire assesses the participants' awareness status of prostate cancer. ....	52

## ABSTRACT

Prostate cancer is a common type of cancer in men Globally. It is the world's second most diagnosed disease and the fifth major cause of cancer-related deaths. In Ethiopia, it is the 3<sup>rd</sup> most common type of cancer. Having awareness of Prostate cancer is the key to early detection and prevention. The major risk factors for prostate cancer were controllable by increasing public awareness. The study aimed to assess the status of awareness about prostate cancer and its associated factors among male patients attending a Urology unit at Tikur Anbessa Specialized Hospital, Addis Ababa, Ethiopia, 2021. A facility-based cross-sectional study was done. Among 241 male patients using a pretest and interviewer-administered questionnaire. The study was done at the Tikur Anbessa Specialized Hospital from February to April 2021. Epidata version 4.6.0 and SPSS 26 version were used to enter and analyze the data. Descriptive statistics and linear regressions were used for the analysis. Simple and multiple linear regression analysis was used to identify factors associated with awareness of prostate cancer. The strength of the association between independent and dependant variables was described using unstandardized  $\beta$  with 95% CI. A total of 250 patients were approached with a response rate of 241(96.4%), with a mean score of prostate cancer awareness (12.6 $\pm$ 10.4) and a proportion of 45%. Families average monthly income >8900ETB ( $\beta$ =2.6, 95%CI:1.1-4.1, P=0.001), heard about prostate cancer ( $\beta$ =5.6, 95%CI:1.5-9.6, P=0.011), having a regular source of care with every six months and above ( $\beta$ =4.3, 95%CI: 2.5-6.1, P<0.001), three times, admission history ( $\beta$ =5.4, 95%CI:1.3-9.5, P=0.009), and health care providers ( $\beta$ =10.7, 95%CI 6.6-14.8, P<0.001) as the major source of information followed by the media ( $\beta$ =9.6, 95%CI 5.4-13.8, P<0.001) were significantly associated with awareness of prostate cancer. Prostate cancer is one of the important health-related problems among men in the world. Therefore, a well-planned health education program should be implemented to address the observed knowledge gaps and raise awareness with a focus on the role of prevention and screening. Additional studies are also, required to investigate the awareness of prostate cancer among men and the Federal Ministry of Health may take preventive methods to increase the level of awareness of prostate cancer among the people.

**Keywords:** Awareness Prostate cancer Urology unit Ethiopia

# 1. INTRODUCTION

## 1.1. Background

Cancer is a group of diseases in which cells in the body grow out of control (1), and it describes several diseases that can affect various organs and parts of the body. Normally, cells multiply and die in an orderly fashion, helping us grow, replace worn tissue, and heal wounds (2). If this process is skewed and the cells get out of control, it creates a mass called a tumor. In benign tumors, cells are kept in one zone and can't extend to different parts of the body, while malignant tumors comprise cancer cells that can spread through the circulation or lymphatic system (3).

Prostate cancer is a disease of the prostate gland. It is the recognized tumor of men and common worldwide (4). The clinical manifestations of prostate cancer may develop gradually, decreased urine flow, urinary incontinence, nocturia, frequency, and difficult urination, blood in the urine, painful ejaculation, and difficulty of erection. If cancer can progress to other organs, bone pain in the pelvis or ribs may occur (5). The uncontrolled risk of developing the disease, such as age, race, and family history, is associated with prostate cancer, however, having awareness on Prostate cancer is identified as the key aspects for quality of prostate cancer care that improved the early detection and prevention of the disease (6).

Prostate cancer is common cancer that occurs in men worldwide (7). It is estimated to be the second most under-diagnosed cancer in men, and it is ranked 5<sup>th</sup> among the causes of cancer in men worldwide (7). In 2015, Prostate Cancer was estimated to be 220,800 of the new cases in the USA, which is 26% of the malignancy among men, while an estimated 27,540 will result in death (8). Europe in Italy in 2017, while 398,708 were associated with prostate cancer, with huge numbers attributable to aging and population growth, while 307,500 deaths occurred in Europe in the same year. Approximately (29.6%) of men used the PSA-test in Italy, which means that the level of screening for prostate cancer was very low and related awareness was needed, such as the risk of prostate cancer and the benefit of prevention (9).

Low awareness of prostate cancer has been recorded after a study in sub-Saharan Africa in Nigeria, with men over 40 years of age less than half-aware of prostate cancer (10). Black men in South Africa have limited access to medical facilities for prostate cancer and consult very late. Of the 100,000 population, only 14 black men were histologically diagnosed with prostate cancer compared to 40.1/100,000 white males in South Africa (11). Overall, the prevalence of prostate cancer is decreased by 10%-30%, raising the understanding of lifestyle changes (12).

According to the FMOH Ethiopia report, non-communicable diseases, including cancers, are developing quickly in Ethiopia similar to other low-income countries. There is a limitation of the structured prostate cancer education or screening program in Ethiopia, the lack of such programs related to a decreased awareness of prostate cancer in increasing the impact of the disease. Individuals will be given broad information about prostate cancer in advance as part of the awareness campaign. It is essential, to evaluate the status of awareness of prostate cancer among inpatients. Therefore, this study tended to assess the understanding of TASH patients about prostate cancer and its related factors in Ethiopia.

## **1.2. Statement of problem**

Cancer is a significant public health concern globally, according to the World Health Organization survey, the 2018 report describes cancer as the world's second leading cause of death and is estimated to increase to 18.1 million new cases, with 9.6 million people dying, and every individual in the world suffers from cancer, which is responsible for one out of six deaths worldwide (13).

According to the Global Burden of Cancer, P CA is the 2<sup>nd</sup> most commonly diagnosed cancer in men worldwide, with 1,276,106 new cases and 358,989 deaths in 2018 (14). Globally, the incidence and mortality of prostatic adenocarcinoma are correlated with rising age (15). The prevalence rate of African-American males was more than that of white males, and their mortality rate was around double that of white males. It is expected that the major causes of this variation are attributable to variations in social, environmental, lifestyle, and genetic variables (16). Since the International Organization for Cancer Research has identified an estimated 2,293,818 cases before 2040, a minor variance in mortality is expected (an increase of 1.05%) (14).

Research on the incidence of prostate cancer in Africa was conducted and the results show that the incidence rate of prostate cancer was 22-23/100,000 of the population in sixteen African countries, while around 19.5/100,000 is recorded as the median incidence rate, the disease continues to increase, even as urbanization rises and positive life expectancy shifts in Africa (17). Furthermore, problems such as insufficient screening, diagnostic procedures, minimum care choices, inadequate testing and training, and limited population-based cancer registration are prevalent, rendering the burden of prostate cancer underestimated in developing countries (18-20).

According to 2018, Addis Ababa Cancer Registry and Global Burden of Cancer Study report, cancer accounts for around 5.8% of total national mortality in Ethiopia. The country's annual cancer incidence is about 60,960 cases, and the mortality rate is over 44,000 (21,22). In Ethiopia, prostate cancer, followed by leukemia and colon cancer, is the third most common cancer among men (11% (23).



According to some studies done in Ethiopia, prostate cancer has recently become more common among Ethiopian men, and the disease is quietly spreading across the country (24, 25). In Ethiopia, the health organization primarily emphasizes the prevention of communicable diseases and there are inadequate screening centers, care facilities, and an unwell-organized referral system. In the event of more incidence and mortality of skilled employees and elderly caregivers, prostate cancer could affect the country's socio-economic, healthcare, and education status (14).

Generally, increasing people's understanding of lifestyle changes, recognizing the risk factors, prevention and regular screening of a person reduces morbidity and mortality of prostate cancer and also improves patient survival. In Ethiopia, the FMOH should concern about the difficulty of non-communicable diseases with special emphasis on cancer, to reduce the incidence and mortality (24). As a result, the use of this research was to decide the status of awareness of prostate cancer and its related variables among men going to the Urology unit at TASH in Addis Ababa, Ethiopia, in 2021.

## **2. LITERATURE REVIEW**

### **2.1. Introduction**

#### **2.1.1. Prostate cancer**

The prostate is both the male reproductive organ accessory gland and a mechanical switch that is regulated by muscles between urination and ejaculation. It is located underneath the urinary bladder and the anterior rectum and produces a fluid that nourishes and protects the sperm cells in the semen, the function, and growth of the prostate are regulated through a hormone known as androgen (testosterone) (26). Normally, cells multiply and die in an orderly manner, helping us to grow, replacing worn-out tissue, and healing injuries, when body cells in the prostate are grown in an uncontrolled manner it is the beginning of prostate cancer (2). Prostate cancer is a disorder of the prostate gland that offers either an asymptomatic disease (27) or a systemic solid type tumor (28). It is marked by a disruption of the prostate architecture, causing abnormal structures of the prostate and an increase in Prostate-Specific Antigen (PSA) serum in the blood (29). A high incidence of prostate cancer is seen in patients who undergo the surgery for benign prostate hyperplasia (BPH) especially in those with advanced age and those with elevated PSA levels of more than 10 mg/ml (30).

#### **2.1.2. Epidemiology of prostate cancer**

Prostate cancer is the most common form of cancer in men, the second most common type of cancer diagnosed in men, and the fifth leading cancer mortality rate in men worldwide (7). It is the second common type of cancer in males worldwide, accounting for 1,276,106 new cases and causing 358,989 deaths (3.8% of all deaths due to most male cancers) in 2018, according to the Global Burden of Cancer 2018 report (31). Although 2,293,818 new cases were published by the International Agency for Cancer Research (IARC) until 2040, a small variant of the mortality rate will be observed (a 1.05% increase) (31).

### **2.1.3. Symptom of prostate cancer**

There are no commonly seen symptoms during the early onset of prostate cancer, however, as the prostate cancer progresses, patients may begin to experience symptoms such as decreased urine flow, urinary incontinence, nocturia, frequent and difficulty in urination, blood in the urine, painful urination and difficulty of erection or painful ejaculation. If cancer can affect other organs, and cause bone pain in the pelvis (32). Patients often perceive these symptoms as harmless, non-specific, or similar to symptoms associated with other less serious conditions, therefore, it is necessary to engage in prostate cancer screening behavior early, as P CA is much more curable in the early onset and early detection (30).

### **2.1.4. Common risk factors of prostate cancer**

According to the American Cancer Society (ACS 2018), the risk factors are the same things that give the body to develop any disease, but having a risk factor doesn't mean the development of the disease (33). The real cause of prostate cancer is elusive but, it has risk factors like advanced age, sex, physical inactivity, smoking, alcohol consumption, poor lifestyle, fatty diet, overweight (obesity), race, and family history of Prostate cancer with age being highlighted as significantly common, almost two out of every three P CA cases are found in men  $\geq 65$  years of age, while prostate cancer is uncommon below 40 years of age (4,34,35).

Globally, Jamaican men of African descent, as well as African-American men, are known to have the highest incidence of P CA (19). Compared to Caucasian men, the risk of developing prostate cancer in black men based purely on ethnicity is estimated to be high (36). Positive family history has also been found to be a significant risk factor for prostate cancer (37). Family history is a common cause of P CA in comparison with the general population (38).

Inherited susceptibility appears to play an additional independent role in the development of prostate cancer, men diagnosed with prostate cancer are almost twice as likely to have a male blood relative (brother or father especially) who has been diagnosed with prostate cancer (39). Besides, prostate cancer risk increases with an increasing number of family members, such that men with two or three first-degree relatives affected have a five- and 11-fold increased risk of developing prostate cancer, respectively (40). Cumulative exposure to cadmium (41) androgens and high-fat diets is also related to prostate cancer risk (42, 43). Sexual behavior and associated exposure to infectious agents like gonorrhea, and humanpapillomavirus increase the risk of P CA (44).

### **2.1.5. Treatments of prostate cancer**

The treatment choices available are determined by the stage of presentation, age, and the presence of other diseases. Treatment for P CA can be invasive and can cause long-term complications such as incontinence or impotence (45). Surgery, such as radical prostatectomy (removal of the prostate gland), and radiation are the most common forms of treatment at the early stage of the disease (46). Hormone therapy and chemotherapy are commonly used in combination with metastatic or advanced stages of the disease. However, chemotherapy and hormone therapy can be used to treat the early stages of the disease (47).

### **2.1.6. Survival status of prostate cancer**

Prostate cancer has a relatively higher survival rate when detected in its early phases, for those diagnosed early with prostate cancer, the five-year survival rate is nearly 100 % (47). The overall five-year survival rate for P CA among blacks is 96% compared to nearly 100% among whites, thus showing the importance of early detection of survival. Compared to 93% of whites, 91% of all P CA among black men are diagnosed at a local or regional stage (48). However, in the advanced stages, the overall five-year survival rate is decreased, and the risk of prostate cancer is higher in black men than in any other racial group, and cancer is often more aggressive at the time of presentation, which is often late, and several studies have found that ethnicity is an important factor in predicting the recurrence of prostate cancer in men (49).

The survival status of prostate cancer patients in Ethiopia is very low, with a maximum survival time of 28 months with a general 2-, 3-and 5-year survival of 57 %, 38.9% %, and 22 % respectively. Increasing people's awareness of lifestyle changes, recognizing individual risk factors and continuous screening decreases morbidity and mortality in prostate cancer and enhances the survival status of patients (50).

#### **2.1.7. Screening and prevention of prostate cancer**

Prostate cancer is a common type of cancer that occurs in men worldwide. Early screening for prostate cancer is associated with longer survival rates and a reduction in mortality rates (51). The main aim of early detection is to reduce the possibility of developing the disease at an asymptomatic stage (52). The screening tests used to investigate this disease include prostate-specific antigen (PSA) and digital rectal examination (DRE) (53). PSA is a male blood protein, that is, tested using a blood sample (54). A high PSA protein level in the blood may be caused by prostate cancer or other prostate issues such as increased prostate gland size or gland inflammation (54). A biopsy may follow if elevated levels of PSA are detected in the blood (55). Prostate cancer is a preventable disease. Many risk factors, such as age, ethnicity, and family history, are uncontrollable or non-modifiable. However, according to ACS and Hopkin's Medical University, several measures can be taken to minimize the incidence of P CA. The measures included stopping smoking and overdrinking, engaging in regular physical exercise, early detection, fighting obesity, eating adequate fruits and vegetables, and talking with health professionals.

#### **2.2. Awareness of prostate cancer**

Awareness is defined as a state of knowing or surely understanding something's condition or being aware that the depend exists (56). Awareness creation about prostate cancer could also be done via social media, health care providers, community-based organizations, and any stakeholders, the delivering information is regarding the risk factors, symptoms prevention, screening modalities, and the advantages of early detection of P CA (9, 57). The awareness of prostate cancer in men of African descent in the USA, Caribbean, and Sub-Saharan Africa (SSA) has low levels of information in contrast to American Hispanic men, consequently the high incidence and mortality rates within those populations (58, 59).

A study was done in, Italy about the awareness and associated factors of prostate cancer, validated that overall, 82.1% of the respondents were heard about the existence of P CA, although 72.7% of the PSA test was heard by respondents and 51.1 % of them had heard about it from their physicians (9). In the cross-sectional study done in Turkey, 47.16% of respondents were reported that health care providers were the main source of information (60). In a study, conducted among Saudi Arab communities 52.1% indicated who had information of prostate cancer, and health care providers 62.4% were the main source of prostate cancer awareness (61).

A cross-sectional study was conducted in Nigeria Anambra state, 74.1% of participants were heard of the presence of prostate cancer, and 76.1% were aware of one or more symptoms of the disease. Difficult urination was the most common presenting symptom in 45.3% of the respondents, at the same time as 87% had been able to identify risk factors for P CA. However, 56.7% of the respondents were aware of prostate-specific antigen screening. With regards to Prostate cancer and the PSA test, the most frequent source of information was media 42.8%, followed by physicians 36.8% (62). In a cross-sectional study done in South Africa among men attending a urology unit, 45.4% of the participants were aware of prostate cancer. Only 38 (11.0%) of patients were aware of the three major symptoms related to prostate cancer. Education and race have been significantly associated with awareness of prostate cancer (11).

According to a study done in Uganda, 54.1% had heard of prostate cancer media as the most common source of information followed by the health care provider, 50.2% could not aware of any risk factor for P CA and but only 9% were known about the PSA test (63). Also, in a study conducted in Sokoto, Nigeria among 300 participants, only 15 (5%) were aware of prostate cancer (64). Similar research was conducted in southwest Nigeria by one hundred and forty-five (47.5 %) respondents who were heard of prostate cancer, while a quarter (25.1%) were aware of PSA, media were essential sources of awareness, with only educational and occupational status having major associations with participants' level of awareness (10).

A cross-sectional study on prostate cancer awareness and its related causes conducted in Rwanda, suggests that among 257 respondents 80% were aware of the presence of prostate cancer and reported the health care provider as the main source of information, 164 (64%) did not recognize the causative factors of prostate cancer, while 68 % of participants were aware of prostate cancer prevention measures, 164 (64%) were aware of prostate cancer tests through PSA testing (65).

### **2.3. Associated factors with Awareness of prostate cancer**

#### **2.3.1. Socio-demographic characteristic**

Among the most important factors associated with prostate cancer awareness were age, place of residency area, occupation status, educational level, and income which are common (35, 57). In developed countries, the factors contributing to cancer awareness and its associated factors are not very far from those from low-income countries (14). The study conducted in, Italy showed that older age and a higher level of education were significantly associated with awareness of prostate cancer (9).

A study conducted in Denmark demonstrated that cancer awareness was found to have strong socioeconomic distribution, as a result, individuals with low levels of education and low incomes were more likely to have unaware of potential cancer symptoms, factors that can influence the likelihood of developing cancer. High income and levels of education were significantly associated with awareness of prostate cancer (66). In Namibia, the study done has reported that urban residency and the richest men are more informed about prostate cancer awareness and they have significantly associated awareness of prostate cancer (67). Also, in a study conducted in southwest Nigeria, 47.5 % of respondents who were aware of prostate cancer media were essential sources of awareness, with only educational and occupational status having major associations with participants' level of awareness (10). In a study done in South Africa among men attending a urology unit, 45.4% of the participants were aware of prostate cancer. Education and race have been significantly associated with awareness of prostate cancer (11).

### **2.3.2. Information related factors**

In a study done in Italy [n=705], 82.1% of the respondents have been heard of the existence of prostate cancer, the most sources of information on prostate cancer were media 60.6% followed by the physician 31.8 %, and friends 31.4%. While 72.7% of respondents had heard about the PSA-test, the most common source of information was a physician 54.4% followed by media 35.8 % and friends 23.4%. 57.9% is indicated that the proportion of awareness of prostate cancer (9).

In the cross-sectional study done in Turkey [n= 159] with 71.06% of the proportion of awareness of prostate cancer and management. 47.16% of respondents were reported that health care providers were the main source of information (60). In a study, conducted in Saudi Arabia among [n= 400] communities, 52.1% indicated participants who had heard of prostate cancer, and the respondents identified physicians 62.4% as the main sources of this information (61).

A cross-sectional study was conducted in Nigeria Anambra state, with 652 participants. Overall, 74.1% of participants were heard of the presence of P CA, and 76.1% were aware of one or more symptoms of the disease. Difficult urination was the most common presenting symptom through 45.3% of the respondents, at the same time as 87% had been able to identify risk factors for P CA. However, 56.7% were aware of Prostate-specific antigen screening and with regards to Prostate cancer and the PSA test, the most frequent source of information was media 279 (42.8%), followed by physicians 240 (36.8%) (62).

According to a study done in Uganda, 54.1% had heard of prostate cancer media as the most common source of information followed by the health care provider, 50.2% could not aware of any risk factor for P CA and but only 9% were known about the PSA test (63). A cross-sectional study on prostate cancer awareness and its related causes conducted in Rwanda, suggests that among 257 respondents with the proportion of 75%, 251 (80%) were aware of the presence of prostate cancer and reported the health provider as the main supplier of information, 164 (64%) did not recognize the causative factors of prostate cancer, while 68 % of participants were aware of prostate cancer prevention measures, 164 (64%) were aware of prostate cancer tests through PSA testing (65).



A cross-sectional study was conducted in Benin [n=402] with 34% of the proportion of awareness of prostate cancer. 71.6% of respondents had been aware of prostate cancer, 29.9% regarded that lower urinary tract symptoms are associated with P CA, and 22% of participants were aware of prostate-specific antigen. Those with tertiary education had associated with awareness of prostate cancer and PSA screening (68).

### **2.3.3. Patient-related factors**

Positive family history has also been found to be a significant risk factor for prostate cancer (37). Family history is a common cause of prostate cancer in comparison with the general population and is associated with the understanding of prostate cancer (38). Men diagnosed with prostate cancer are twice as likely to have a male blood relative (especially, brother, and father) who has been diagnosed with the P CA (39). Also, the risk of prostate cancer rises the number of affected family members, with men with two or three first-degree relatives having a fivefold and eleven-fold increased risk of developing prostate cancer, respectively. The aim of any type of cancer with a family history should have been to provide enough information to capacitate awareness about the disease (40).


In the cross-sectional study done at the University of Texas [n=267], among young and black men of the university 155 (58.08%) of respondents had a regular source of care or regular check-up (69). The regular source of care /check-ups is periodic health assessments or examinations. It helps to the awareness of the health status of patients in risk factors, symptoms, early diagnosis, prevention, and treatments of many diseases (70).

According to a study done in South Africa, frequent admission of the patients encourages the awareness of the patients concerning their health and health-related situations. The number of participants who thought about different factors of health care service ranged from 18.9% to 84.1%. Almost half of the respondents were aware of their admission reasons and management plans. The relationship between health care providers and patient experience should include encouraging awareness of patients' health and health-related issues (71).

The study that assessed the awareness of prostate cancer and its related variables in Ethiopia is not known. Recently, in Ethiopia, the incidence rate of prostate cancer has silently risen, reaching 11% (23), and also, the survival status of the patients is very low (50). Therefore, to overcome this challenge, further research is aimed at not only the TASH communities that this study considered but also the different population groups with focus flaws to be part of the prevention of prostate cancer in Ethiopia. This study was aimed to assess the status of awareness of prostate cancer and its associated factors among male patients attending the urology unit at Tikur Anbessa Specialized Hospital, Addis Ababa, Ethiopia, 2021.

## 2.4. Conceptual Framework

The conceptual framework placed below shows the effect of independent variables on the dependent variable which is adapted from different kinds of literature (32, 33, 34, 57, 69, 71).



**Figure 1:** The conceptual framework of awareness status of prostate cancer and associated factors among patients attending in Urology at Tikur Anbessa Specialized Hospital, Addis Ababa, Ethiopia, 2021

## **JUSTIFICATION OF THE STUDY**

Prostate cancer in Ethiopia is the third most common cancer in men and is the cause of morbidity and mortality (23). Ethiopia is one of the parts of the developing country, and because of economic obstacles, it is a major challenge for the nation to control and manage cases effectively. Several epidemiological studies performed in different populations show that there is a substantial gap between the countries in the incidence and mortality of prostate cancer. Even though primary prevention is a successful approach to reducing the cost-effective burden of the disease, no previous studies have been performed to determine the status of awareness of prostate cancer in Ethiopia. Besides, the goal of this study will provide different researchers who prefer to study related subjects with an addition to the baseline information.

## **SIGNIFICANCE OF THE STUDY**

The reason behind this research is to determine the understanding of P CA and its related factors in TASH. The finding of the study will improve a better understand of risk factors, symptoms, screening, and prevention of P CA, in Ethiopia. The study's results also developed basic information that will support the improvement of the country's effective prevention programs. Disease prevention is a national priority for improving patient care. The results of this study will be subsequently used as a fundamental tool for stakeholders to establish strategies, initiatives, and preventive campaign programs to raise awareness among people on prostate cancer.

This scarcity of awareness about such a study in the field of cancer can be utilized as a source of information for future researchers interested in carrying out further studies, and the findings can be useful for researchers, educators, clinicians, and experts interested in evaluating the understanding of prostate cancer and its related factors among male prostate cancer patients in the study.

### **3. OBJECTIVES OF THE STUDY**

#### **3.1. General Objectives**

- To assess the status of awareness of prostate cancer and its associated factors among male patients attending in Urology unit at Tikur Anbessa Specialized Hospital, Addis Ababa, Ethiopia, 2021

#### **3.2. Specific Objective**

- To assess the status of awareness of prostate cancer among male patients participating in the Urology unit at Tikur Anbessa Specialized Hospital, Addis Ababa, Ethiopia, 2021.
- To determine factors associated with prostate cancer awareness among male patients attending the Urology unit at Tikur Anbessa Specialized Hospital, Addis Ababa, Ethiopia, 2021.

## **4. MATERIALS AND METHODS**

### **4.1. Study area and study period**

The study was performed from February 8, 2021, to March 8, 2021, at the Tikur Anbessa Specialized Hospital, located in the Ethiopian capital city of Addis Ababa. It is the largest and most well-known public hospital in Ethiopia, established in the early 1960s. TASH is a center of teaching and referral hospital with approximately 800 hundred inpatient beds. It is the only cancer referral hospital in Ethiopia. This study was conducted at the outpatient department of the Urology unit at the TASH. The most common urology cases seen in the urology unit were BPH, Urolithiasis, STI, and UTI. In the TASH Urology unit, Urologists, Residents, Surgeons, and Nurses are working together to complete their daily tasks (72, 73).

### **4.2. Study Design**

A descriptive facility-based cross-sectional study design was used.

### **4.3. Population**

#### **4.3.1. Source Population**

All male patients who were attending at TASH from February 8 to March 8, 2021

#### **4.3.2. Study Population**

All male patients who attended the Urologic unit of TASH during the data collection period fulfill inclusion criteria.

### **4.4. Inclusion and exclusion criteria**

#### **4.4.1. Inclusion criteria**

All ages >18 years old male patients who attended in outpatient at the Urology unit of TASH during the data collection period were included.

#### **4.4.2. Exclusion criteria**

- Men patients with mental disorder and critically sick
- Patients who are unable to give verbal consent and sign on the written consent.

#### 4.5. Sample Size Determination

The sample size was calculated using a method for estimating a single proportion and a correction formula. The sample size for this cross-sectional study was calculated according to Cochran and William guidelines, 5% marginal error, 95% confidence level,  $\alpha=0.05$ , and a 10% non-response rate, assuming a population percentage of 50% because the proportion of awareness of prostate cancer is not determined in Ethiopia yet. Based on this assumption, the actual sample size for the research was applied as follows (74).

$$n = \frac{(Z \alpha/2)^2 p (1-p)}{d^2}$$

**Where: -**

**n**= Desired sample size

**Z**=Value of corresponding to a 95% level of significance=1.96

**P** = Proportion (50%)      **q=1-p**

**d**= Margin of error 5% (0.05)

Therefore, using the above single population proportion formula the sample size can be calculated,

$$n = \frac{(1.96)^2 \times 0.5(1-0.5)}{(0.05)^2} = 384$$

Where the study population is below 10,000 reduction formula was applied (74).

$$nf = \frac{n}{1 + n/N}$$

Where **nf**=desired sample size **n**= the calculated sample size **N**= total population (Patients found in Urology units of the TASH)

$$\frac{384}{1 + (384 / 535)} \quad Nf = 225 \text{ (desired sample size)}$$

Therefore, the study was done on a total sample size of **250** males, including a non-response rate of 25 (**10%**).



#### **4.6. Sampling procedure**

A systematic sampling technique was used to collect desired samples from the TASH Urology unit, by using the patient's appointment logbook as a sampling frame. The average population of last year (2020) of male patients on a monthly in the Urology Unit of TASH was [N = 535] from these, 27 patients were seen daily. In all cases, [n = 250] from these, each day, an average of 13 patients were sampled to maximize the representative sample.  $K = N/n$ , 2, and K is between 1 and 2. First comer patients who were registered in the Health Management and Information System (HMIS) registry book took as a first sample and then every two intervals until the samples were obtained with a day at the Urology unit. Hence, the Urology unit is providing health care services to patients who have prostate and prostate-related health problems.

#### **4.7. Study Variables**

##### **Dependent variable (DV)**

- ❖ Awareness of Prostate cancer

##### **Independent Variables (IV)**

- ❖ **Socio-demographic variables** include

- ✓ Age
- ✓ Place of residency,
- ✓ Marital status
- ✓ Higher level of education level
- ✓ Income, and
- ✓ Occupation.

- ❖ **Information related factors:**

- ✓ Heard about prostate cancer
  - Health professionals
  - Media (TV, Radio, social media)
  - Peer groups/friends

- ❖ **Patient-related factors**

- ✓ Family history
- ✓ Regular source of care or regular checkup
- ✓ Admission history of the health institution.

#### **4.8. Operational Definition**

❖ **Level of Awareness of prostate cancer:**

The Respondents, prostate cancer awareness score was assessed by the 28 yes or no items of the awareness questionnaire. The total score was calculated or computed out of 100, which has a range from 0 to 100. Awareness was scored by the proportion (percentage) of correctly answered.

❖ **Urology unit:**

Is a surgical specialty commonly that treats diseases of the male urinary tract and male reproductive organs. Worldwide About 20%-62% of prostate and prostate-related problems are seen in it (75).

#### **4.9. Data collection tool and Data collection procedure**

Data were collected from the participants through an interviewer-administered questionnaire that was adapted with modification from different published research and Cancer awareness measurements (CAM) toolkit version 2.1 from the University of London (9,65,76). The contents of the questionnaire included socio-demographic characteristics, information-related factors, patient-related factors, and awareness of prostate cancer items. Items of the questionnaire include yes/no questions. The interview was taking place in the outpatient departments at the TASH's Urology Units. The English version of the questionnaire was developed. A bilingual translator translated it into Amharic and then back into English, and it was reviewed by a senior oncologist and senior researchers in the field of study. Based on previous data collection experience and fluency in the local language, two qualified nurses (BSc) were recruited for the data collection. Before one week of the actual data collection, a pretest was done on 5% (13) of the sample size by the primary researcher which was held in the oncology unit. Challenges with clarification, pattern, relevance, accuracy, and time permitted in the instrument were addressed during the pretest. After this, the internal consistency (Cronbach's- $\alpha$ ) of this study was 0.88 which, is considered adequate. In addition to ensuring data accuracy, two days of role-play training were given to data collectors on how to check the completeness, handling, ethical concerns of the data, and safeguard confidentiality and privacy. Also, encourage data collectors to adhere to the COVID-19 pandemic prevention guideline.

#### **4.10. Data Quality Management**

To manage the quality of data the following measures were taken, the questionnaire was adapted with modification from the Cancer awareness measurement (CAM) and published research. The pre-test was done and the required corrections were made. The primary investigator provided training for the data collectors. There was supervision, daily, and checking on the data collection questionnaire. Moreover, the collected information was coded, cleaned, and explored via the primary investigator earlier than analysis. The entire data collection period was monitored by the primary investigator.

#### **4.11. Data processing and Analysis**

The study was computed using descriptive statistics and linear regression analysis using epi data version of 4.6.0 software to prevent data entry error and exported to SPSS version 26 for further statistical analysis. Recoding, categorizing, computing, and other statistical analyses were made. Descriptive analysis (Mean, standard deviations, frequency, and percentage) was used to analyze the independent variables. Tables and graphs were used to show the findings. The awareness of prostate cancer score was recorded as a continuous scale in the SPSS and scored by the proportion of correctly answered.

First, performed simple linear regression to select the candidate variables for multiple linear regression. All variables having a p-value  $\leq 0.25$  during simple linear regression were selected for the multiple linear regression. After the multiple linear regression analysis, variables having a p-value less than 0.05 were having statistical significance with awareness of prostate cancer. The strength of the association between independent and dependent variables was described using unstandardized  $\beta$  with 95% CI.

After developing a dummy variable table to describe the variables associated with the response (outcome variables). However, before fitting the linear regression model, the assumptions of linearity were tested and fulfilled using a scatter plot, normality was checked using a histogram and p-p plots, homoscedasticity was satisfied by plotting two scatter plots of standardized residuals against the standardized expected values, and the data were distributed normally.

Finally, multicollinearity was checked by examining both the tolerance and Variability inflation factor (VIF). Multicollinearity is calculated, indicating just how much of the variability of the listed independent variables was not determined by the other predictor variables in the given model. All of the tolerance scores in the model were  $>0.10$  and the Variability inflation factor (VIF) values were below 10, implying that multicollinearity could not exist. R square statistic in the model also described 0.8 of the variances which determine the good appropriateness of the model used.

#### **4.12. Ethical Consideration**

The study was conducted following the declaration of Helsinki. An ethical clearance letter was obtained from the ethics Institutional Review Board Addis Ababa University, College of Health Sciences, school of nursing and midwifery (protocol N0 36/21SNM). Further permission was received from the urology unit at TASH. An information sheet was prepared and read to all eligible participants, their participation was voluntary and written consent was obtained. Confidentiality was maintained throughout the process. Detailed information was given to study subjects if the need arises. The interview was conducted in well lighted, ventilated, clean, and quiet place attached to the unit to respect their dignity. Immediately following data collection, leaflets on prostate cancer were distributed to respondents to raise their awareness. The content of the leaflet was focused on the symptoms, risk factors, early detection (early screening), and prevention of prostate cancer, as prepared from the given literature.

#### **4.13. Dissemination Study Results**

The results of the study will be submitted to the AAU, College of Health Sciences, School of Nursing, and Midwifery. The paper will be presented at workshops, seminars. Finally, the paper will be published in local and international reputable journals for possible publication.

## 5. RESULTS

A total of 250 patients approached and 241 participated in this study making a response rate of 96.4%.

### 5.1. Socio-demographic characteristics of the respondents

Nearly three-fourths of the respondents 180 (74.7%) were from urban. The mean age of the respondents was 52.3 (SD  $\pm$  13.6) years with a minimum and maximum age of 28 to 97 years respectively. Regarding marital status, above half 157 (65.1%) of the respondents were married. In terms of the educational level of study participants, 106 (44%) had college and above. About 103 (42.7%) of respondents were employed. Almost half of the respondents' 114 (47.3%) monthly income was Between 2251-8900 ETB. The majority of participants 141 (58.5%) had heard about prostate cancer, and health care providers were the major source of information 69 (48.9%) followed by the media 56 (39.7%) [[Table 1](#)].

**Table 1 Socio-demographic characteristics of respondents in TASH, Addis Ababa, Ethiopia, 2021 [n=241]**

<b>Variable</b>	<b>Frequency (N)</b>	<b>Percentage (%)</b>
<b>Age continuous</b>	<b>Mean = 52.3</b>	<b>SD = (± 13.5)</b>
<b>Age category</b>		
≤40yrs	59	24.4
>40 yrs.	182	75.6
<b>Place Residency</b>		
Urban	180	74.7
Rural	61	25.3
<b>Marital status</b>		
Single	36	14.9
Married	157	65.1
Others <sup>a</sup>	48	19.9
<b>Occupation status</b>		
Employee	103	42.7
Merchant	60	24.9
Others <sup>b</sup>	78	32.4
<b>A higher level of education</b>		
College and above	106	44.0
Secondary Education (9-12)	69	28.6
Primary school (1-8)	51	21.2
Others <sup>c</sup>	15	6.2
<b>Monthly Income In ETB</b>		
Low income (≤ 2250)	73	30.3
Middle income (2251-8900)	114	47.3
High income (>8900)	54	22.4
<b>Heard about P CA</b>		
YES	141	58.5
NO	100	41.5
<b>Source of information</b>		
Health care providers	69	48.9
Friends	16	11.3
Media <sup>d</sup>	56	39.7

**Note:** **Other** <sup>a</sup> widowed and divorced. **Others** <sup>b</sup> Retired, Farmer, and Student. **Others** <sup>c</sup> unable to write and read, able to write and read, Media <sup>d</sup> TV, Radio and social media

## 5.2. The patient-related factors of the respondents

About 54 (22.4%) respondents had a family history of prostate cancer while 105 (43.6%) of respondents had a regular source of care for their health, and from those participants, almost half, 116 (48.1%) of had an admission history in the health institution [Table 2].

**Table 2: The patient-related factors of the Respondents in TASH, Addis Ababa, Ethiopia, 2021 [n=241]**

Variables	Frequency (N)	Percentage (%)
<b>Family history n=241</b>		
YES	54	22.4
NO	187	77.6
<b>Family member n=54</b>		
Father	39	72.2
Others <sup>a</sup>	15	19.7
<b>Regular source for care n=241</b>		
YES	105	43.6
Not have	136	56.4
<b>Duration of regular care n=105</b>		
< 6 months	65	61.9
≥ 6 months	40	38.1
<b>Admission history n=241</b>		
YES	116	48.1
NO	125	51.9
<b>Duration of admission n=116</b>		
1 time	23	19.8
2 times	61	52.5
3 times	17	14.6
≥ 4times	15	12.9

**Note: Others<sup>a</sup>** Father and mother family



### **5.3. Awareness of prostate cancer and its components score**

The minimum and maximum scores for the awareness of prostate cancer were 0 and 100 respectively out of 28 questionnaires. The mean score was 12.6 (SD $\pm$ 10.4) from 28. The percentage of the prostate cancer awareness score of the respondents was 45% of the total expected score, seen in [Table 3].

#### **5.3.1. Awareness of risk factors and symptoms score**

The mean risk factors and symptoms score of the respondents was 4.1 (SD $\pm$ 3.6) and (2.6 (SD $\pm$ 2.5) with the proportion of 41.2% and 43.8%, respectively. Many of the study participants, 119 (49.4%) and 72 (29.9%) were reported that aging and family history are both major non-controllable risk factors for prostate cancer respectively. Almost half of the study participants were reported that the following modifiable risk factors respectively, Smoking cigarettes 120(49.8%), lack of fruits and vegetables 114 (47.3%) being overweight (obesity) 112 (46.5%), and drinking alcohol 107(44.4%). Also, the most common symptoms reported by respondents were difficulty urinating 133 (55.2%), frequent urination 128 (53.1%), and hematuria 115 (47.7%), seen in [Table 3].

#### **5.3.2. Awareness on screening and prevention score**


The mean screening and prevention score of the respondents was 1.3 (SD  $\pm$ 1.2) and 4.5(SD $\pm$ 3.9) with the proportion of 44.7% and 49.5% respectively. According to this study, overall prostate cancer screening included two tests, a PSA and a DRE test, and study participants were reported that a rectal examination of 110 (45.6 %) and a PSA test of 81 (33.6 %), respectively. Among the respondents, 120 (49.8%) were reported that prostate cancer is being a disease that can be managed to avoid. For prevention, the majority of respondents 155 (64.3%), to the onset of prostate cancer talked to health professionals as the first intervention to avoid prostate cancer followed by use adequate fruits and vegetables 132(54.8%) seen in [Table 3].

**Table 3 Distribution of study participants on the awareness of prostate cancer in TASH, Addis Ababa, Ethiopia, 2021 [n=241].**

<b>variable</b>	<b>Questionnaire (Do you think that...</b>	<b>Yes N (%)</b>	<b>No N (%)</b>
	Aging can cause P.CA?	119 (49.4)	122 (50.6)
	Family history can cause P.CA?	72 (29.9)	169 (70.1)
<b>Risk factors</b>	Drinking alcohol can cause P.CA?	107 (44.4)	134 (56.4)
<b>[n=10]</b>	Smoking cigarettes can cause P.CA?	120 (49.8)	121 (50.2)
	Lack of adequate fruit and vegetables can cause P.CA?	114 (47.3)	127 (52.7)
	Poor physical activity can cause P.CA?	101 (41.9)	140 (58.1)
	Having multiple sexual partners can cause P.CA?	105 (43.6)	136 (56.4)
	Obesity /overweight can cause P.CA?	112 (46.5)	129 (53.5)
	Genetics can cause P.CA?	72 (29.9)	169 (70.1)
	Prior prostate disease (Prostatitis) can cause P.CA?	71 (29.5)	170 (70.5)
	Frequent urination is prostate cancer-related symptoms?	128 (53.1)	113 (46.9)
	Difficult urination is prostate cancer-related symptoms?	133 (55.2)	108 (44.8)
<b>Symptoms</b>	Back pain is prostate cancer-related symptoms?	85 (35.3)	156 (64.7)
<b>[n=6]</b>	Pelvic bone pain is prostate cancer-related symptoms?	84 (34.9)	157 (65.1)
	Hematuria is prostate cancer-related symptoms?	115 (47.7)	126 (52.3)
	Painful ejaculation is prostate cancer-related symptoms?	89 (36.9)	152 (63.1)
	Early screening can increase the survival of patients?	134 (55.6)	107 (44.4)
<b>Screening</b>	Have you ever known about DRE?	109 (45.2)	131 (54.4)
<b>[n=3]</b>	Have you ever known about PSA?	80 (33.2)	160 (66.4)
	Do you think that P.CA is a preventable disease?	120 (49.8)	121 (50.2)
	Can prevent P CA by stopping smoking?	117 (48.5)	124 (51.5)
	Can prevent P CA by stopping drinking alcohol?	119 (49.4)	122 (50.6)
<b>Prevention</b>	Can prevent P CA by Early screening?	113 (46.9)	128 (53.1)
<b>[n=9]</b>	Can prevent P CA by Doing Regular physical exercise?	110 (45.6)	131 (54.4)
	Can prevent P CA by Combat (fight) obesity?	99 (41.1)	142 (58.1)
	Can prevent by Reduce having multiple sexual partners?	110 (45.6)	131 (54.4)
	Can prevent P CA by talking with health professionals?	155 (64.3)	86 (35.7)
	Can prevent P CA by using adequate Fruits and vegetables	132 (54.8)	109 (45.2)

### 5.3.3. Distribution of the proportion score of awareness on prostate cancer

The proportion of prostate cancer awareness score of the respondents was 45% from the total expected score, whereas, the percentage score of the components were 41.2% with a mean score of 4.1 (SD= $\pm$ 3.6) for risk factors, 43.8% with a mean score of 2.6 (SD $\pm$ 2.5) for symptoms, 44.7% with a mean score of 1.3 (SD  $\pm$ 1.2) for screening, and 49.5% with a mean score of 4.5(SD $\pm$ 3.9) for prevention of, awareness of prostate cancer, respectively, as seen in [Figure 2].



**Figure 2: Distribution of the proportion score of prostate cancer awareness and its' components from the total expected score among male patients in the Urology unit at TASH, Addis Ababa, Ethiopia, in 2021.**

**Table 4: Predictors of awareness of prostate cancer based on the simple linear regression analysis model, in TASH, Addis Ababa, Ethiopia, 2021 [n=241].**

Variable	Mean	SD ( $\pm$ )	Crude	
			Unstandardized Coefficients(95%CI)	p-value
<b>Place of residency</b>				
Rural	7.98	9.59	1	1
Urban	14.10	10.19	6.1 (3.1-9)	<0.001
<b>Marital status</b>				
Married	11.22	10.41	1	1
Single	13.61	9.80	-2.3 (-6.1-1.3)	0.2
Widowed	11.75	10.42	-1.8 (-6.6-2.9)	0.4
Divorced	8.89	10.29	-4.7 (-8.8-0.5)	0.02
<b>Occupation</b>				
Employee	15.51	11.15	1	1
Student	15.25	11.18	-0.2 (-10 - 9.5)	0.958
Merchant	11.18	9.59	-4.2 (-0.7- 0.1)	0.007
Retired	13.83	10.87	-1.6 (-5.4-2)	0.376
Farmer	5.18	8.32	-10.3 (-13.6- 6.6)	< 0.001
<b>Monthly income in ETB</b>				
2251-8900	12.30	10.24	1	1
<2250	10.36	10.22	-1.6 (-4.6-1.3)	0.274
>8900	16.63	9.88	4.6 (1.3- 7.9)	0.007
<b>Heard about PCA</b>				
No	2.40	5.91	1	1
Yes	19.75	5.82	17.3 (15.8-18.8)	<0.001
<b>Source of information</b>				
No	2.40	5.91	1	1
Friends	18.75	5.42	16.5 (13.5-19.5)	<0.001
Health care providers	20.62	5.42	18.3 (16.6-20.3)	<0.001
Media	19.25	6.26	17 (15-18.8)	<0.001

<b>Family history</b>				
No	10.05	10.14	1	1
Yes	21.20	5.31	11.5 (8.3-13.9)	<0.001
<b>Family member</b>				
Mother family	20.57	9.11	1	1
Father	20.90	4.66	10.4 (7.1-13.7)	<0.001
Brother	23.50	4.30	12.8 (6-19.5)	<0.001
<b>Regular source of care</b>				
No	8.84	9.63	1	1
Yes	17.36	9.31	8.5 (6.1-10.9)	<0.001
<b>Duration of regular care</b>				
No	8.84	9.63	1	1
< 6months	16.65	9.90	7.8 (4.9-10.6)	<0.001
≥ 6 months	18.52	8.24	9.6 (6.3-13)	<0.001
<b>Admission history</b>				
No	11.18	10.56	1	1
Yes	14.03	10.01	2.8 (0.2-5.4)	<0.03
<b>Duration of admission</b>				
≥ 4 times	12.11	11.55	1	1
1 time	16.41	10.28	5.1 (1.01-9.3)	0.01
2 times	13.21	10.12	1.9 (-1.2-5)	0.2
3 times	13.88	10.18	2.6 (-2.5-7.8)	0.3

**Note: Media:** -Television, Radio, social media, **ETB:** -Ethiopian birrs, **SD:** -Standard deviation

Since the age and level of education variables do not fit the simple linear regression analysis model, they were excluded because their p-value is greater than 0.25. Multiple linear regression models were used with variables that fitted with a p-value of  $\leq 0.25$ , as seen in [Table 4].

#### 5.4. Associated factors with the awareness of prostate cancer

In simple linear regression analysis, residency of the respondents, marital status, occupational status, families average monthly income, heard about prostate cancer, source of information, family history, regular source of care with a duration of a regular checkup, and admission history for the specific prostate problem with duration of admission was fitted with the awareness of prostate cancer. Also, in multiple linear regression analysis, family average monthly income > 8900 ETB, heard about prostate cancer, health care provider, friends, and media from the source of information, family history  $\geq$  6 months and above a duration of regular source of care, and three (3) times of admission history were significantly associated with prostate cancer awareness.

By holding the effect of all other variables in the model, the study participants had an average family monthly income > 8900 ETB, had increased the score of awareness on prostate cancer by factors of 2.9 times as compared to respondents who had less than 8900 ETB monthly income ( $\beta=2.9$ , 95%CI: 1.2-4.6,  $P=0.001$ ). Study participants who heard about prostate cancer increased the awareness of prostate cancer score by a factor of 5.3 times as compared to respondents who didn't hear ( $\beta=5.3$ , 95%CI: 1.2-9.4,  $P=0.011$ ). Study participants who have a family history of prostate cancer increased the awareness of P CA score by a factor of 6.9 times as compared to respondents who had no family history ( $\beta=6.9$ , 95%CI: 3.1-10.7,  $P< 0.001$ ).

Respondents who have source information through health care provider, friends, and media (TV, radio, social media) had raised the awareness of prostate cancer score by a factor of 10.8 times, 10.4 times, 9.5 times as compared to those who have not of information ( $\beta=10.8$ , 95%CI 6.7-15,  $P<0.001$ ,  $\beta=10.4$ , 95%CI:5.8-14.9,  $P<0.001$ ,  $\beta=9.5$ , 95%CI:5.3-13.7,  $P<0.001$ ) respectively. The Respondents who have a regular source of care with every six months and above had increased the awareness of prostate cancer score by a factor of 4.3 times as compared to those who have less than six-month routine checkup for their health ( $\beta=4.3$ , 95%CI: 2.5-6.1,  $P<0.001$ ). The study participants who have 3 times, admission history had raised the awareness of P CA score by a factor of 5.4 times as compared to those who have less and more frequent admission history with the specific prostate problem ( $\beta=5.4$ , 95%CI:1.3-9.5,  $P=0.009< 0.001$ ), seen in [Table 5].

**Table 5: Predictors of awareness of prostate cancer based on the multiple linear regression analysis models, in TASH, Addis Ababa, Ethiopia, 2021 [n=241].**

Variables	Adjusted Unstandardized $\beta$ coefficient (95% CI)	P-value	Collinearity	
			Tolerance	VIF
<b>Monthly income</b>				
2251-8900	1	1	1	1
<2250	1.5 (-0.3-3.3)	0.10	0.52	1.89
> 8900 ETB	2.9 (1.2-4.6)	0.001	0.75	1.32
<b>Hear about PCA</b>				
NO	1	1	1	1
YES	5.3 (1.2-9.4)	0.011	0.92	1.88
<b>Information source</b>				
Haven't information	1	1	1	1
Health care providers	10.8(6.7-15)	< 0.001	0.11	8.4
Friends	10.4 (5.8-14.9)	< 0.001	0.10	9.46
Media	9.5 (5.3-13.7)	< 0.001	0.29	3.39
<b>Family history</b>				
NO	1	1	1	1
YES	6.9 (3.1-10.7)	< 0.001	0.14	6.71
<b>Regular source of care</b>				
Haven't regular care	1	1	1	1
< 6 months	1.8 (0.32-3.5)	0.025	0.73	1.36
$\geq$ 6 months	4.3 (2.5-6.1)	< 0.001	0.80	1.23
<b>Duration of admission</b>				
$\geq$ 4 times	1	1	1	1
1 time	1.4 (-1.0-3.1)	0.32	0.83	1.20
2 times	0.14 (-1.3-1.6)	0.85	0.84	1.18
3 times	5.4 (1.3-9.5)	0.009	0.34	2.90

**Note:** -Media (TV, radio, social media), **ETB:** -Ethiopian birrs, **VIF:** -Variance inflation factor, **(95% CI):** - 95% confidence interval.

## 6. DISCUSSION

Having awareness of Prostate cancer is identified as the key aspect for the quality of prostate cancer care that improved the early detection and prevention of the disease (6). This study investigated that the proportion of prostate cancer awareness and associated factors among male patients attend in the urology at TASH, Addis Ababa, Ethiopia

Our study showed that the proportion of prostate cancer awareness was 45%. This study's findings of awareness score also lower than the results of a study done in Rwanda 75% (65). The major discrepancy among the previous studies and in our study might be due to Study in Rwanda was conducted directly on patients who have an appointment for prostate cancer, this is make difference in the individual awareness toward prostate cancer.

In contrast, this finding is also contrary to a study conducted in Benin (68), which indicated that a small score was reported than our study about prostate cancer awareness, which is only (34%). This difference may be related to the difference in the study population, the study was conducted on the general population but our study was conducted on patients who came to the urology department. This indicates patients with specific health problems had more awareness than the general population (75).

This study demonstrated that families with a high monthly income had a significant impact on participants' awareness (77). This is supported by a study conducted in Denmark and Namibia, which explored a strong socioeconomic distribution in cancer awareness, with individuals with low family income having a poor awareness of symptoms, risk factors, prevention, and screening (66, 67). People with more incomes were more concerned about their health than those with lower incomes. Furthermore, economic development in one country is increasing school enrollment and educational attainment, which improves people's educational levels and health status. Furthermore, people with a high income were encouraged to learn more about their health and health-related status.



Regarding the sources of information about prostate cancer, 141 (58.5%) of the respondents were heard about the existing prostate cancer from a different source. the respondents were heard about the existing prostate cancer from different sources. Health care providers, media, and friends were significantly associated with awareness of prostate cancer. Health care providers as the most common source of information, followed by the media (TV, radio, and social media). This is supported by the other study done in the following countries which indicated the main source of information was health care providers and the media. Research conducted in Saudi, and Rwanda, found out the main source of information was being health care providers (61,65).

Also, studies were done in Italy, Nigeria, and Uganda noticed that the main source of information was being media (9, 62,63). This may be due to that the Ethiopian media did not provide adequate information and awareness to prostate cancer or health care providers were gave more information than the media.

Nearly one-fourth of the respondents 22.4 % had a family history of prostate cancer. Positive family history is a significant risk factor for prostate cancer and is significantly associated with the awareness of prostate cancer (37). Men diagnosed with prostate cancer are twice as likely to have a male blood relative (especially, brother, and father) who has been diagnosed with the P CA (39). Also, the risk of prostate cancer rises the number of affected family members, with men with two or three first-degree relatives having a fivefold and eleven-fold increased risk of developing prostate cancer, respectively. The aim of any type of cancer with a family history should have been to provide enough information to capacitate awareness about the disease's risk factors, symptoms, early detection, and prevention. It also allows for the implementation of an initial management plan and follow-up action for the possibility of a family member's susceptibility (40).

Furthermore, in this study, 43.5% of respondents who have a routine source of care had associated with prostate cancer awareness. Of respondents who have a regular source of care every six months and more had significantly associated with Awareness of prostate cancer. This study is in line with a study done at Texas university (69).

The regular source of care is periodic health assessments or examinations. It is relevant to health professionals or health institutions where the person usually goes to his/her health and health-related conditions if he/she is ill or needs advice. When patients received regular and routine care services from health care providers, their awareness was improved accordingly (69).

Nearly half of the participants 48.1% had a history of admission to a health facility for prostate and prostate-related problems, from those, who have 3 times, admission history is significantly associated with awareness of prostate cancer as compared to those who have less frequent admission history. This is supported by studies done in South Africa (71). According to the European Charter of Patients' Rights (78), a patient's right to be aware of their health condition during their admission is a basic human right and an important part of modern health care practice.

Frequent admission of the patients also encourages the awareness of the patients concerning their health and health-related situations. Globally, during admission, the number of participants who have awareness of different factors of health care service ranged between 18.9% and 84.1% (71). As a result, patients who have had previous admissions are more aware of their wellbeing and health-related problems than those who have not. Since the relationship between health care providers and patients should include empowering patients to be more aware of their health and health-related issues.

## **7. STRENGTH AND LIMITATION OF THE STUDY**

The study instrument was comprehensive, pretested, and modified before the actual data collection. The data were double entered and validated using the Epidata Version 4.6.0 entry before analysis. However, since the findings are restricted to a sample of Tikur Anbessa specialized hospital patients, thus limiting their generalizability to the whole country. Our study sample size was small, which limits our generalizability of the findings on awareness of prostate cancer and its associated factors. So, it needs a large sample size to incorporate other aspects of respondents' awareness of prostate cancer. The research may also be limited by the fact that these were based on the participants' self-report, which can increase social desirability bias.

## **8. CONCLUSION AND RECOMMENDATIONS**

### **8.1. Conclusion**

In conclusion, the proportion of awareness score among respondents of male patients attending Tikur Anbess specialized hospital was low relative to previous studies. More than half of the study participants were having an awareness score below the mean value. While health care providers were the main source of information followed by the media. Families' average monthly income, heard about prostate cancer, having a regular source of care every six months and more, a three-times, admission history, and source of information were all significantly associated with Prostate cancer awareness. This strong association between prostate cancer awareness and associated factors will be essential in understanding and controlling the disease.

## **8.2. Recommendations**

Based on the study's findings, the following important recommendations are forwarded to the relevant bodies on prostate cancer awareness, prevention, early detection, and treatment program facilitators, policymakers, and researchers who are involved in this area.

### **To the Federal ministry of health**

Better if implemented prostate cancer early screening and detection program to improve early treatment results and survival outcomes. It is essential to raise awareness about prostate cancer prevention, screening, diagnosis, and early treatment through collaboration with government and private media. Better if given special attention to the quietly rising prostate cancer in the country.

### **To Tikur Anbessa Specialized Hospital and health care providers**

Health care providers could enhance awareness about prostate cancer accordingly. Health professionals could emphasize health information dissemination (HID) on the risk factors, symptoms, early screening, and prevention, Health-care facilities should pay special attention to health education for patients who visit them to raise awareness about prostate cancer.

### **For future researchers**

Future studies with larger sample sizes will be recommended to better understand the local risk factors, symptoms, screening, and prevention for prostate cancer in our country. In the future, the researchers should have to study and investigate furtherly with additional variables, emphasis on community and facility-based level.

## 9. REFERENCE

1. Hausman DM. What Is Cancer? *Perspect Biol Med.* 2019;62(4):778-784. DOI: 10.1353/pbm.2019.0046. PMID: 31761807.
2. Rousselle P, Braye F, Dayan G. Re-epithelialization of adult skin wounds: Cellular mechanisms and therapeutic strategies. *Adv Drug Deliv Rev.* 2019 Jun; 146:344-365. DOI: 10.1016/j.addr.2018.06.019. Epub 2018 Jul 5. PMID: 29981800.
3. Seyfried TN, Huysentruyt LC. On the origin of cancer metastasis. *Crit Rev Oncog.* 2013;18(1-2):43-73. DOI: 10.1615/critrevoncog.v18.i1-2.40. PMID: 23237552; PMCID: PMC3597235.
4. Bashir MN. Epidemiology of Prostate Cancer. *Asian Pac J Cancer Prev.* 2015;16(13):5137-41. DOI: 10.7314/apjcp.2015.16.13.5137. PMID: 26225642.
5. Smith RA, Andrews KS, Brooks D, Fedewa SA, Manassaram-Baptiste D, Saslow D, Wender RC. Cancer screening in the United States, 2019: A review of current American Cancer Society guidelines and current issues in cancer screening. *CA Cancer J Clin.* 2019 May;69(3):184-210. DOI: 10.3322/caac.21557. Epub 2019 Mar 15. PMID: 30875085.
6. Wolf AM, Wender RC, Etzioni RB, Thompson IM, D'Amico AV, Volk RJ, Brooks DD, Dash C, Guessous I, Andrews K, DeSantis C. American Cancer Society guideline for the early detection of prostate cancer: update 2010. *CA: a cancer journal for clinicians.* 2010 Mar;60(2):70-98.
7. Banerjee S, Kaviani A. Worldwide prostate cancer epidemiology: Differences between regions, races, and awareness programs. *International Journal of Clinical and Experimental Medical Sciences.* 2016;2.
8. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. *CA Cancer J Clin.* 2015 Jan-Feb;65(1):5-29. doi: 10.3322/caac.21254. Epub 2015 Jan 5. PMID: 25559415.
9. Morlando M, Pelullo CP, Di Giuseppe G. Prostate cancer screening: Knowledge, attitudes, and practices in a sample of men in Italy. A survey. *PLoS One.* 2017 Oct 12;12(10):e0186332. DOI: 10.1371/journal.pone.0186332. PMID: 29023514; PMCID: PMC5638517.
10. Ojewola RW, Oridota ES, Balogun OS, Ogundare EO, Alabi TO, Banjo OO, Laoye A, Adetunmbi B, Adebayo BO, Oluyombo R. Knowledge, attitudes and screening practices regarding prostatic diseases among men older than 40 years: a population-based study in Southwest Nigeria. *Pan Afr Med J.* 2017 Jun 30; 27:151. DOI: 10.11604/pamj.2017.27.151.10605. PMID: 28904679; PMCID: PMC5567951.

11. Mofolo N, Betshu O, Kenna O, Koroma S, Lebeko T, Claassen FM, Joubert G. Knowledge of prostate cancer among males attending a urology clinic, a South African study. *Springerplus*. 2015 Feb 10; 4:67. DOI: 10.1186/s40064-015-0824-y. PMID: 25713760; PMCID: PMC4329121.
12. Shephard RJ. Physical Activity and Prostate Cancer: An Updated Review. *Sports Med*. 2017 Jun;47(6):1055-1073. DOI: 10.1007/s40279-016-0648-0. PMID: 27844337.
13. World Health Organization (WHO, 2018). About Cancer. [internet], [cited ,2020 Dec 15]; Available from; <https://www.who.int/news-room/fact-sheets/detail/cancer>.
14. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin*. 2018;68(6):394–424.
15. Zhou CK, Check DP, Lortet-Tieulent J, Laversanne M, Jemal A, Ferlay J, Bray F, Cook MB, Devesa SS. Prostate cancer incidence in 43 populations worldwide: an analysis of time trends overall and by age group. *International journal of cancer*. 2016 Mar 15;138(6):1388-400.
16. Panigrahi GK, Praharaj PP, Kittaka H, Mridha AR, Black OM, Singh R, Mercer R, Van Bokhoven A, Torkko KC, Agarwal C, Agarwal R. Exosome proteomic analyses identify inflammatory phenotype and novel biomarkers in African American prostate cancer patients. *Cancer medicine*. 2019 Mar;8(3):1110-23.
17. Adeloye D, David RA, Aderemi AV, Iseolorunkanmi A, Oyedokun A, Iweala EE, Omoregbe N, Ayo CK. An estimate of the incidence of prostate cancer in Africa: a systematic review and meta-analysis. *PloS one*. 2016 Apr 13;11(4): e0153496.
18. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. *International journal of cancer*. 2015 Mar 1;136(5): E359-86.
19. Jemal A, Bray F, Forman D, O'Brien M, Ferlay J, Center M, Parkin DM. Cancer burden in Africa and opportunities for prevention. *Cancer*. 2012 Sep 15;118(18):4372-84.
20. Fadlelmola FM. Cancer registries and cancer genomics research in east Africa: challenges and lessons learned. *Int Clin Pathol J*. 2016;2(4):67-76.
21. FMOH E. National Cancer Control Plan 2016–2020. Addis Ababa Dis Prev CONTROL Dir Ed Dir DPAC. 2015;
22. Memirie ST, Habtemariam MK, Asefa M, Deressa BT, Abayneh G, Tsegaye B, et al. Estimates of Cancer Incidence in Ethiopia in 2015 Using Population-Based Registry Data. *J Glob Oncol*. 2018 Mar 28;(4):1–11.

23. Addis Ababa City Cancer Registry E. Addis Ababa City Cancer Registry Cancer Incidence Report. African Cancer Registry Network, 2019 [internet], [cited ,2020 Dec,20]; Available from <https://afcrn.org/membership/members/100-Addisababa>  
[www.iccp-portal.org/sites/default/files/plans/NCCP%20Ethiopia%20Final%20261015.pdf](http://www.iccp-portal.org/sites/default/files/plans/NCCP%20Ethiopia%20Final%20261015.pdf)
24. Federal Ministry of Health; Ethiopia: National Cancer Control Plan 2016–2020 October 2015: Addis Ababa Ethiopia, [internet], [cited,2020, Dec 15]; available from <https://www.iccp-portal.org/>
25. Solomon S, Mulugeta W. Diagnosis and Risk Factors of Advanced Cancers in Ethiopia. *Journal of cancer prevention*. 2019 Sep 30;24(3):163-72.
26. Aaron L, Franco OE, Hayward SW. Review of prostate anatomy and embryology and the etiology of benign prostatic hyperplasia. *Urologic Clinics*. 2016 Aug 1;43(3):279-88.
27. Persec Z, Persec J, Sovic T, Romic Z, Herak MB, Hrgovic Z. Metastatic prostate cancer in an asymptomatic patient with an initial prostate-specific antigen (PSA) serum concentration of 21,380 ng/ml. *Oncology Research and Treatment*. 2010;33(3):110-2.
28. Jinga V, Csiki IE, Manolescu A, Iordache P, Mates IN, Radavoi D, Rascu S, Badescu D, Badea P, Mates D. Replication study of 34 common SNP s associated with prostate cancer in the Romanian population. *Journal of cellular and molecular medicine*. 2016 Apr;20(4):594-600.
29. Perera M, Papa N, Christidis D, Wetherell D, Hofman MS, Murphy DG, Bolton D, Lawrentschuk N. Sensitivity, specificity, and predictors of positive 68Ga–prostate-specific membrane antigen positron emission tomography in advanced prostate cancer: a systematic review and meta-analysis. *European urology*. 2016 Dec 1;70(6):926-37.
30. Gunda D, Kido I, Kilonzo S, Nkandala I, Igenge J, Mpondo B. Prevalence and associated factors of incidentally diagnosed prostatic carcinoma among patients who had a transurethral prostatectomy in Tanzania: a retrospective study. *Ethiopian Journal of health sciences*. 2018;28(1):11-8.
31. Rawla P. Epidemiology of prostate cancer. *World journal of oncology*. 2019 Apr;10(2):63.
32. Chua ME, Lapitan MC, Morales Jr ML, Roque AB, Domingo JK, Philippine Urological Residents Association. 2013 Annual National Digital Rectal Exam Day: impact on prostate health awareness and disease detection. *Prostate International*. 2014 Mar 1;2(1):31-6.
33. Rock CL, Thomson C, Gansler T, Gapstur SM, McCullough ML, Patel AV, Andrews KS, Bandera EV, Spees CK, Robien K, Hartman S. American Cancer Society Guideline for Diet and Physical Activity for cancer prevention. *CA: A Cancer Journal for Clinicians*. 2020 Jun 9.



34. Pernar CH, Ebot EM, Wilson KM, Mucci LA. The epidemiology of prostate cancer. *Cold Spring Harbor Perspectives in Medicine*. 2018 Dec 1;8(12): a030361.
35. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. *CA: a cancer journal for clinicians*. 2016 Jan;66(1):7-30.
36. Badal S, Aiken W, Morrison B, Valentine H, Bryan S, Gachii A, Ragin C. Disparities in prostate cancer incidence and mortality rates: Solvable or not? *The Prostate*. 2020 Jan;80(1):3-16.
37. Randazzo, M., Müller, A., Carlsson, S., Eberli, D., Huber, A., Grobholz, R., Manka, L., Mortezavi, A., Sulser, T., Recker, F. and Kwiatkowski, M., 2016. Positive family history as a risk factor for prostate cancer in a population-based study with organized prostate-specific antigen screening: results of the Swiss European Randomised Study of Screening for Prostate Cancer (ERSPC, Aarau). *BJU international*, 117(4), pp.576-583.
38. Ren ZJ, Cao DH, Zhang Q, Ren PW, Liu LR, Wei Q, Wei WR, Dong Q. First-degree family history of breast cancer is associated with prostate cancer risk: a systematic review and meta-analysis. *BMC Cancer*. 2019 Dec 1;19(1):871.
39. Xu J, Sun J, Zheng SL. Prostate cancer risk-associated genetic markers and their potential clinical utility. *Asian journal of andrology*. 2013 May 6;15(3):314.
40. Scher HI, Leibel SA, Fuks Z, Cordon-Cardo C, Scardino PT. Cancer of the prostate. DeVita, Hellman, and Rosenberg's *Cancer Principles and Practices of Oncology*, 2015:932-80.
41. Wu CC, Pu YS, Wu HC, Yang CY, Chen YC. Reversed association between levels of prostate-specific antigen and levels of blood cadmium and urinary cadmium. *Chemosphere*. 2011 May 1;83(8):1188-91.
42. Odedina FT, Dagne G, LaRose-Pierre M, Scrivens J, Emanuel F, Adams A, Pressey S, Odedina O. Within-group differences between native-born and foreign-born Black men on prostate cancer risk reduction and early detection practices. *Journal of Immigrant and Minority Health*. 2011 Dec 1;13(6):996-1004.
43. Di Sebastiano KM, Mourtzakis M. The role of dietary fat throughout the prostate cancer trajectory. *Nutrients*. 2014 Dec;6(12):6095-109.
44. Caini S, Gandini S, Dudas M, Bremer V, Severi E, Gherasim A. Sexually transmitted infections and prostate cancer risk: a systematic review and meta-analysis. *Cancer epidemiology*. 2014 Aug 1;38(4):329-38.

45. Lehto US, Helander S, Taari K, Aromaa A. Patient experiences at diagnosis and psychological well-being in prostate cancer: A Finnish national survey. *European Journal of Oncology Nursing*. 2015 Jun 1;19(3):220-9.
46. Wennick A, Jönsson AK, Bratt O, Stenzelius K. Everyday life after radical prostatectomy—A qualitative study of men under 65 years of age. *European Journal of Oncology Nursing*. 2017 Oct 1; 30:107-12.
47. Tourville EA, Nguyen MM. Prostate cancer detection by using digital rectal examination: contemporary practice patterns in the United States. *Clinical genitourinary cancer*. 2013 Sep 1;11(3):263-9.
48. Fajardo-Zapata Á, Jaimes-Monroy G. Knowledge, Perception, and Disposition on the Prostate Examination in Men Older Than 40 Years Old. *Revista de la Facultad de Medicina*. 2016 Apr;64(2):223-8.
49. Taylor KL, Turner RO, Davis III JL, Johnson L, Schwartz MD, Kerner J, Leak C. Improving knowledge of the prostate cancer screening dilemma among African American men: an academic-community partnership in Washington, DC. *Public Health Reports*. 2016 Nov 30.
50. Beksisa J, Getinet T, Tanie S, Diribi J, Hassen HY. Survival and prognostic determinants of prostate cancer patients in Tikur Anbessa Specialized Hospital, Addis Ababa, Ethiopia: A retrospective cohort study. *PloS one*. 2020 Mar 5;15(3): e0229854.
51. Wu I, Modlin CS. Disparities in prostate cancer in African American men: what primary care physicians can do. *Cleve Clin J Med*. 2012 May 1;79(5):313-20.
52. Qaseem A, Barry MJ, Denberg TD, Owens DK, Shekelle P. Screening for prostate cancer: a guidance statement from the Clinical Guidelines Committee of the American College of Physicians. *Annals of internal medicine*. 2013 May 21;158(10):761-9.
53. Barbosa AI, Castanheira AP, Edwards AD, Reis NM. A lab-in-a-briefcase for rapid prostate-specific antigen (PSA) screening from whole blood. *Lab on a chip*. 2014;14(16):2918-28.
54. Pérez-Ibave DC, Burciaga-Flores CH, Elizondo-Riojas MÁ. Prostate-specific antigen (PSA) as a possible biomarker in non-prostatic cancer: a review. *Cancer epidemiology*. 2018 Jun 1; 54:48-55.
55. Gilgunn S, Conroy PJ, Saldova R, Rudd PM, O'Kennedy RJ. Aberrant PSA glycosylation a sweet predictor of prostate cancer. *Nature Reviews Urology*. 2013 Feb;10(2):99.
56. McPhetres J. Oh, the things you don't know: awe promotes awareness of knowledge gaps and science interest. *Cognition and Emotion*. 2019 Nov 17;33(8):1599-615.

57. Mottet N, Bellmunt J, Bolla M, Briers E, Cumberbatch MG, De Santis M, Fossati N, Gross T, Henry AM, Joniau S, Lam TB. EAU-ESTRO-SIOG guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent. *European urology*. 2017 Apr 1;71(4):618-29.
58. Brawley OW. Trends in prostate cancer in the United States. *Journal of the National Cancer Institute Monographs*. 2012 Dec 1;2012(45):152-6.
59. Mahal BA, Berman RA, Taplin ME, Huang FW. Prostate cancer-specific mortality across Gleason scores in black vs non-black men. *Jama*. 2018 Dec 18;320(23):2479-81.
60. Sungur M, Caliskan S. Awareness of prostate cancer diagnosis and management among Turkish males: a cross-sectional study from Çorum. *The Aging Male*. 2019 Apr 17:1-4.
61. Arafa MA, Rabah DM, Wahdan IH. Awareness of general public towards cancer prostate and screening practice in Arabic communities: a comparative multi-center study. *Asian Pacific journal of cancer prevention*. 2012;13(9):4321-6.
62. Oranusi CK, Mbieri UT, Oranusi IO, Nwofor AM. Prostate cancer awareness and screening among male public servants in Anambra State, Nigeria. *African Journal of Urology*. 2012 Jun 1;18(2):72-4.
63. Nakandi H, Kirabo M, Semugabo C, Kittengo A, Kitayimbwa P, Kalungi S, Maena J. Knowledge, attitudes and practices of Ugandan men regarding prostate cancer. *African Journal of Urology*. 2013 Dec 10;19(4):165-70
64. Awosan KJ, Yunusa EU, Agwu NP, Taofiq S. Knowledge of prostate cancer and screening practices among men in Sokoto, Nigeria. *Asian Journal of Medical Sciences*. 2018 Oct 29;9(6):51-6.
65. Benurugo G, Munyambaraga E, Chironda G, Bisanukuri E. Awareness on prostate cancer and screening practices among men attending outpatient at a referral hospital in Kigali, Rwanda: A quantitative study. *International Journal of Africa Nursing Sciences*. 2020 Jan 1; 13:100241.
66. Hvidberg L, Pedersen AF, Wulff CN, Vedsted P. Cancer awareness and socio-economic position: results from a population-based study in Denmark. *BMC Cancer*. 2014 Dec;14(1):1-3.
67. Kangmennaang J, Mkandawire P, Luginaah I. What prevents men aged 40–64 years from prostate cancer screening in Namibia. *Journal of cancer epidemiology*. 2016 Jan 10;2016.
68. Agbugui JO, Obarisiagbon EO, Nwajei CO, Osaigbovo EO, Okolo JC, Akinyele AO. Awareness and knowledge of prostate cancer among men in Benin City, Nigeria. *Journal of Medicine and Biomedical Research*. 2013;12(2):42-7.

69. Ogunsanya ME, Brown CM, Odedina FT, Barner JC, Adedipe TB, Corbell B. Knowledge of prostate cancer and screening among young multiethnic black men. *American Journal of Men's Health*. 2017 Jul;11(4):1008-18.
70. Varshini A, Rani SL, Brundha MP. Awareness of annual doctor checkups among the general population. *Drug Invention Today*. 2020 Feb 15;14(2).
71. Mabuza LH, Omole OB, Govender I, Nzimande JV, Schoeman HS. Inpatients' awareness of admission reasons and management plans of their clinical conditions at a tertiary hospital in South Africa. *BMC health services research*. 2015 Dec;15(1):1-9.
72. Background of Tikur Anbessa Hospital College of Health Sciences [Internet]. [cited 2020 Dec.20]. Available from: <http://www.aau.edu.et/chs/tikur-anbessa-specializedhospital/background-of-tikur-anbessa-hospital/>
73. Tikur Anbessa Specialized Hospital Urology Unit manager office. 2020.
74. Cochran WG, William G Sampling Techniques. New York: John Wiley & Sons. Inc; 1977.
75. Yeboah ED. Prevalence of Benign Prostatic Hyperplasia and Prostate Cancer in Africans and Africans in the Diaspora. *J West Afr Coll Surg*. 2016;6(4):1.
76. Connor K, Hudson B, Power E. Awareness of the Signs, Symptoms, and Risk Factors of Cancer and the Barriers to Seeking Help in the UK: Comparison of Survey Data Collected Online and Face-to-Face. *JMIR Cancer*. 2020;6(1): e14539.
77. Average monthly salary in Ethiopia [cited 2021 February 20]. Available from: <http://www.salaryexplorer.com/salary-survey.php?loc=69&loctype=1>
78. Active Citizen Network (2006). European Charter of Patients' Rights. [https://ec.europa.eu/health/ph\\_overview/co\\_operation/mobility/docs/health\\_services\\_co108\\_en.pdf](https://ec.europa.eu/health/ph_overview/co_operation/mobility/docs/health_services_co108_en.pdf). [Cited 2020 December 13]



**COLLEGE OF HEALTH SCIENCE  
SCHOOL OF NURSING AND MIDWIFERY  
DEPARTMENT OF NURSING.**

**10. APPENDIX**

**APPENDIX- A: INFORMATION SHEET**

**Dear respondents,** my name is \_\_\_\_\_ I am here to collect information for a study called, "Awareness of prostate cancer and associated factors among male patients attending a Urology unit, at Tikur Anbessa Specialized Hospital " The research is being conducted by Tilaye Gebru. You have been selected as a participant in this study, and the questionnaire normally takes 30 minutes to complete.

**Name of the Organization:** AAU, CHS, School of Nursing and Midwifery Department of Oncology Nursing.

**Name of the Sponsor:** AAU

**Objective:** This study aims to determine the status of awareness among male patients attending a Urology unit at Tikur Anbessa Specialized Hospital, Addis Ababa, Ethiopia, 2021, of prostate cancer and its related factors.

**Risk and discomfort:** There are no physical or psychological risk during data collection

**Benefits:** For those patients who would be included in this study, the study had no direct benefit. The indirect advantage of the study for the participant and other clients in the program is obvious.

**Confidentiality:** The information was collected without the names of the clients. The data obtained from this study project will be kept confidential and stored in a file. Besides, except for the prosecutor, it will not be disclosed to anybody and it will be stored in a computer password in a key and locked device.

**Person to contact:** If you would like to hear more about the research and its undertakings, you can contact the committee at the address below.

Cell phone: +251927109676,

E-mail: [tilaye.gebru@haramaya.edu.et](mailto:tilaye.gebru@haramaya.edu.et)

## **APPENDIX- B: CONSENT FORM**

I understand the purpose of the research, the benefits, my right to voluntary participation, confidently, and without any victimization, withdrawal from the study. I had the chance to ask questions and I answered them to my satisfaction.

I freely consent to participate in this study.

Agreed \_\_\_\_\_

Don't agree \_\_\_\_\_

Date \_\_\_\_\_ Sign \_\_\_\_\_

**Thank you for your cooperation.**

**APPENDIX - C: QUESTIONNAIRE (ENGLISH VERSION)**

**Table 6. 1 PART I: The question has to do with background information.**

If you are willing to answer the question Please put (√) the answer option and write the appropriate response to the given space.

<b>NQ</b>	<b>Items</b>	<b>Participant response</b>
101	How old are you?	_____
102	Where is your residency place?	1. Urban                      2. Rural
103	What is your marital status?	1. Single                      3. Widowed 2. Married                      4. Divorced
104	What is your occupation?	1. Employee                      4. Farmer 2. Marchent                      5. Student 3. Retired                      6. Other specify
105	What is your higher level of education?	1. Unable to write and read 2. Able Read and write 3. Primary Education (1-8) 4. Secondary Education (9-12) 5. College and above 6. Other specify
106	How much monthly income do you get in Birr?	_____
<b>Information related Questionnaire</b>		
107	Have you heard of prostate cancer before?	1. YES                      2. NO
108	If your response is Yes, where can you get the information?  If your response is No, skip to the next question.	1. TV 2. Radio 3. Social Media 4. Health care providers 5. Friends 6. Other, Specify



<b>Patients' history-related Questionnaires</b>		
109	Do you have a history of prostate cancer in your family?	1. YES      2. NO
110	If your answer is yes, who has a prostate problem? If your response is No, skip to the next question.	1. Father 2. Brother 3. In mother family 4. Other, specify-----
111	Do you have a regular source of care/checkups?	1. YES      2. NO
112	If your response is yes, how long have you been seeing your physician?	1. < 6 months 2. 6 months to < 1 year 3. 1 to 5 years 4. 5 years and above 5. Other specify -----
113	Do you have a hospital admission with a prostate problem?	1. YES      2. NO
114	If your response is yes, how many times admit to the hospital?	1. 1 time                  3. 3times 2. 2 times                4. More ≥4 times

**Table 6. 2 PART II: The questionnaire assesses the participants' awareness status of prostate cancer.** If you are willing to answer the question, please put (√) the answer option and write the appropriate response to the given space.

<b>S. N<sub>0</sub></b>	<b>QUESTIONNAIRES ABOUT RISK FACTORS</b>	<b>RESPONSE</b>
201	Do you think one of the risk factors for prostate cancer is aging?	1. YES      2. NO
202	Do you think family history is one of the risk factors for prostate cancer?	1. YES      2. NO
203	Do you think alcohol consumption is one of the risk factors for prostate cancer?	1. YES      2. NO
204	Do you think a smoking cigarette is one of the risk factors for prostate cancer?	1. YES      2. NO
205	Do you think that lack of vegetables and fruits within the diet is one of the risk factors for prostate cancer?	1. YES      2. NO
206	Having poor physical activity is may cause cancer of the prostate?	1. YES      2. NO

207	Having multiple sexual partners causes cancer of the prostate.	1. YES    2. NO
208	One of the risk factors for cancer of the prostate is obesity/overweight?	1. YES    2. NO
209	Prostate cancer may be caused by genetics?	1. YES    2. NO
210	Prior prostate disease (Prostatitis) may cause cancer of the prostate?	1. YES    2. NO
<b>QUESTIONNAIRES ABOUT SYMPTOMS OF PROSTATE CANCER</b>		
211	Do you think that frequent urination is one of the symptoms related to prostate cancer?	1. YES    2. NO
212	Do you think difficult urination is one of the symptoms of cancer of the prostate?	1. YES    2. NO
213	Do you think back pain is one of the prostate cancer-related symptoms?	1. YES    2. NO
214	Do you think pelvic bone pain is one of the symptoms of prostate cancer?	1. YES    2. NO
215	Do you think hematuria is one of the prostate cancer-related symptoms?	1. YES    2. NO
216	Do you think that painful ejaculation is one of the prostate cancer-related symptoms?	1. YES    2. NO
<b>QUESTIONNAIRES ABOUT SCREENING OF PROSTATE CANCER</b>		
217	Do you think that early screening increases the survival of patients with prostate cancer?	1. YES    2. NO
218	Have you ever known about DRE for patients with prostate problems?	1. YES    2. NO
219	For <b>218</b> If your response is Yes, where can you get the information?	1. TV 2. Radio 3. Social Media 4. Health care providers 5. Friends 6. Other, Specify-----

220	Have you ever known about PSA tests for patients with prostate problems?	1.YES	2.NO
221	For <b>220</b> If your response is Yes, where can you get the information?	1. TV 2. Radio 3. Social Media 4. Health care providers 5. Peer groups/ Friends 6. Other, Specify-----	
<b>Awareness of the Preventive measures of prostate cancer</b>			
Identify any prostate cancer preventive method you know; multiple answers are allowed			
N <sup>o</sup>	Questionnaire	Responses	
		YES	NO
222	Prostate cancer is a preventable disease?		
223	Can prevent cancer of the prostate by quitting smoking?		
224	Can prevent cancer of the prostate by quitting drinking?		
225	Can prevent cancer of the prostate by Regular screening?		
226	Can prevent cancer of the prostate by doing Regular physical exercise (walking, running)?		
227	Can prevent cancer of the prostate by Combat (fight) obesity?		
228	Can prevent cancer of the prostate by Reduce having multiple sexual partners?		
229	Can prevent P CA by talking to health professionals?		
230	Can prevent P CA by using fruits and vegetables in the diet?		

**የመረጃ ቅጽ: -I**

**ውድ ተጠያቂ :ስሜ -----ይባላል እኔ የጥናቱን ባለቤት **ጥላይ ገብሩን****

ወክዬ ስገኝ ይህ መጠይቅ የአዲስ አበባ ዩኒቨርሲቲ ጤና ሳይንስ ኮሌጅ የነርስ እና የአዋላጂ ነርስ ትምህርት በጥቁር አንበሳ ስፔሻላይዝድ ሆስፒታል ከሚገኙ ህመምተኞች መካከል የሽንት ፊኛ ጨፍ እጢ ግንዛቤ እና ተጓዳኝ ጉዳዮችን ለማጥናት ተዘጋጅቷል እርሶም በጥናቱ ላይ ተሳታፊ እንዲሆኑ ተመርጠዋል። በመሆኑም በጥናቱ ላይ ተሳታፊ ለመሆን ፈቃደኛ ከሆኑ ከ30 ደቂቃ በላይ የማይወስድ ጥያቄ እጠይቅዎታለሁ ።

**የድርጅቱ ስም:** የአዲስ አበባ ዩኒቨርሲቲ, ጤና ሳይንስ ኮሌጅ, የነርስ እና የአዋላጂ ነርስ ትምህርት ቤት የአዋቂዎች ነርስ ትምህርት ክፍል

**የድጋፍ አድራጊ ስም:** አዲስ አበባ ዩኒቨርስቲ

**የጥናቱ ዓላማ-**በጥቁር አንበሳ ስፔሻላይዝድ ሆስፒታል የተመላላሽ ሕክምና ክፍል በሚከታተሉ የወንዶች ህመምተኞች መካከል የፕሮስቴት ካንሰር ግንዛቤ እና ተያያዥ ተጓዳኝ ሁኔታዎችን ለመገምገም ።

**ስጋት፤** በዚህ ጥናት በመሳተፍዎ ምንም የአካልም ሆነ የስነ -ልቦና ጉዳት አይደርስብዎትም።

**ጥቅማ ጥቅሞች :** ጥናቱ ውስጥ ለተከተቱት ታካሚዎች ቀጥተኛ የሆነ ጥቅም የለዉም።ይሁን እንጂ በፕሮግራሙ ውስጥ ለተሳተፉ እና ለሌሎች ደንበኞች ምርምር ማድረግ ቀጥተኛ ያልሆነ ጥቅም ግልጽ ነው።

**ምስጢራዊነት:**ሚስጢራዊነት ለማረጋገጥ በምርጫው ላይ ያለው መረጃ ደንበኞቹን ስም ሳይገልጽ ይሰበሰባል፣ ከዚህ የምርምር ፕሮጀክት የተሰበሰበው መረጃ በምስጢር የሚጠበቅ በተጨማሪ, ከአጥኝው በቀር ለማንም አይገለጽም እና በቁልፍ ከተዘጋ በኋላ በተቆለፈ ስርአት አማካኝነት በኮምፕዩተር ማቆሚያ ክፍል ውስጥ እንዲቀመጥ ይደረጋል።

**መገኘት ያለበት ግለሰብ:** ማናቸውም ጥያቄ ካልዎት ከሚከተለው ግለሰብ ጋር መገናኘት ይችላሉ (መርማሪና) እና በፈለጉት ጊዜ መጠየቅ ይችላሉ።

**ጥላይ ገብሩ**

**ስልክ ቁጥር:** +251927109676,

**ኢሜል:** [tilaye.gebru@haramaya.edu.et](mailto:tilaye.gebru@haramaya.edu.et)

**የስምምነት ቅጽ: II**

የጥናቱን ሁኔታ ጥቅም በፈቃደኝነት የመሳተፍ መብት ምስጢር የተጠበቀ እንደሆነና ከጥናቱ በፈለኩት ጊዜ መውጣት እንደምችል ተረድቻለሁ።

**ስለሆነም በጥናቱ ላይ ለመሳተፍ**

- 1. እስማማለሁ
- 2. አልስማም

የተሳታፊው ፊርማ \_\_\_\_\_ ቀን: \_\_\_\_\_

**ለትብብርዎ በቅድሚያ እናመሰግናለን።**

**APPENDIX -D: QUESTIONNAIRE AMHARIC VERSION**

**መመሪያ 1 ይህ ጥያቄ ዳራ መረጃ (background information) ጋር የተያያዘ ነው :: ጥያቄውን ለመመስ ፍቃደኛ ከሆኑ እባክዎን የመልስ አማራጭን (✓) ያስቀምጡ እና ለተሰጠው ቦታ ተገቢውን ምላሽ ይጻፉ:**

ተ. ቁ	I. ስነ-ህዝብ መረጃ ጥያቄ	ምላሽ
101	ዕድሜዎት ስንት ነው?	_____
102	ነዋሪነትዎ የት ነው?	1. በከተማ                      2. በገጠር
103	የጋብቻ ሁኔታዎ እንዴት ነው?	1. ያላገባ                      3. ሚስቱ የሞተችበት 2. ያገባ                      4. ትዳሩን የፈታ
104	ስራዎት ምንድነው?	1. ሰራተኛ/ተቀጣሪ                      4. ግብርና 2. ነጋዴ                      5. ተማሪ 3. ጡረተኛ                      6. ሌላ ካለ (ይጥቀሱ)
105	ከፍተኛ የትምህርት ደረጃዎት ምንድነው ነው?	1. ማንበብና መጻፍ የማይችል 2. ማንበብና መጻፍ የሚችል 3. የመጀመሪያ ደረጃ (1- 8) 4. ሁለተኛ ደረጃ (9-12) 5. ኮሌጅ እና ከዚያ በላይ 6. ሌላ ካለ (ይጥቀሱ)-----
106	ወርሐዊ ገቢዎት በብር ስንት ይሆናል?	_____
107	ስለ የሽንት ፊኛ ጫፍ እጢ ሰምተው ያውቃሉ?	1. አዎ                      2. አላውቅም
108	ለ <b>107</b> <sup>ኛው</sup> ጥያቄ መልስዎት አዎ ከሆነ እሌን መረጃ ከየት ሊሰጡት ቻሉ? ለ <b>107</b> <sup>ኛው</sup> ጥያቄ መልስዎት አላውቅም ከሆነ ወደሚቀጥለው ጥያቄ ይሻገሩ	1. ከቴሌቪዥን 2. ከራዲዮ 3. ከማህበራዊ ሚዲያ (internet) 4. ከህክምና ባለሙያ 5. ከጓደኛ                      6. ሌላ ካለ (ይጥቀሱ)-
109	ከቤተሰብዎ መካካል በሽንት ፊኛ ጫፍ እጢ የታመመ ሰው አለ?	1. አዎ                      2. የለም

110	መልስዎ አዎ ከሆነ ከቤተሰብ መካከል ማነው? መልስዎት የለም ከሆነ ወደሚቀጥለው ጥያቄ ይሻገሩ	1. አባት 2. ወንድም	3. የእናት ቤተሰብ 4. ሌላ ካለ -----
111	መደበኛ የጤና እንክብካቤ ከህክምና ባለሙያ ጋር ያደርጋሉ?	1. አዎ	2. አላደርግም
112	መልስዎ አዎ ከሆነ በሐኪምዎ በምን ያህል ጊዜ ውስጥ ይታያሉ?	1. ከ 6 ወራት በታች 2. ከ 6 ወራት - 1 ዓመት 3. ከ 2 -5 ዓመታት 4. ከ >5 ዓመታት 5. ሌላ ካለ (ይጥቀሱ)-----	
113	ከሽንት ፊኛ ጋር በተያያዘ ችግር ምክንያት ሆስፒታል ተኝተው ታክሞው ያውቃል?	1. አዎ	2. አለውቅም
114	መልስዎ አዎ ከሆነ ለምን ያህል ጊዜ?	1. 1 ጊዜ 2. 2 ጊዜ	3. 3 ጊዜ 4. ከ $\geq 4$ ጊዜ በላይ

**ክፍል 2: - ይህ ጥያቄ የተሳታፊዎችን ስለ ሽንት ፊኛ ጤና እጣ ያላቸውን ግንዛቤ መገምገሚያ ስለሆነ :: ጥያቄውን ለመመስ ፍቃደኛ ከሆኑ እባክዎን ምላሽዎን የሚወክልውን አማራጭ ያክበቡ ወይም (✓) ይጠቀሙ ::**

ተ. ቁ	II. ለሽንት ፊኛ ጤና እጣ የሚያጋልጡ የግንዛቤ ጥያቄዎች	ምላሽ	
201	የእድሜ መጨመር ለሽንት ፊኛ ጤና እጣ አጋላጭ ከሆኑ ምክንያቶች አንዱ ነው ብለው ያስባሉ?	1. አዎ	2. አላስብም
202	ለሽንት ፊኛ ጤና እጣ አጋላጭ ከሆኑት ምክንያቶች መካከል አንዱ በቤተሰብ መካከል የተከሰተ (የሚከሰት) የሽንት ፊኛ ጤና እጣ ነው ብለው ያስባሉ?	1. አዎ	2. አላስብም
203	አልከል መጠጣት ለሽንት ፊኛ ጤና እጣ አጋላጭ ከሆኑ ምክንያቶች አንዱ ነው ብለው ያስባሉ?	1. አዎ	2. አላስብም
204	ሲጋራ ማጨስ ለሽንት ፊኛ ጤና እጣ አጋላጭ ከሆኑ ምክንያቶች አንዱ ነው ብለው ያስባሉ?	1. አዎ	2. አላስብም

205	ባአመጋገባችን ላይ አነስተኛ አትክልት እና ፍራፍሬ መኖር ለየሽንት ፊኛ ጫፍ እጢ ከሚያጋልጡ ምክንያቶች አንዱ ነው ብለው ያስባሉ?	1. አዎ	2. አላስብም
206	መደበኛ የአካል ብቃት እንቅስቃሴ አለማከናወን የሽንት ፊኛ ጫፍ እጢ ተጋላጭነትን ሊጨምር ይችላል ።	1. አዎ	2. አላስብም
207	ከብዙ ሰዎች ጋር የግብረ ሥጋ ግኑኝነት መፈጸም የሽንት ፊኛ ጫፍ እጢ ተጋላጭነትን ያስከትላል ።	1. አዎ	2. አላስብም
208	የሽንት ፊኛ ጫፍ እጢ ከሚያስከትሉት አጋላጭች አንዱ ምክንያት ከመጠን በላይ ውፍረት / ከመጠን በላይ የሆነ ክብደት ነው ።	1. አዎ	2. አላስብም
209	የሽንት ፊኛ ጫፍ እጢ በዘር ሊከሰት ይችላል ።	1. አዎ	2. አላስብም
210	የተደጋገመ / ቀድሞ የነበረ/ የሽንት ፊኛ ጫፍ ህመም የሽንት ፊኛ ጫፍ እጢን ሊያስከትል ይችላል።	1. አዎ	2. አላስብም
<b>III. የሽንት ፊኛ ጫፍ እጢ ምልክቶች የግንዛቤ ጥያቄዎች</b>			
211	ቶሎ ቶሎ(በማጣደፍ) ሽንት መሸናት ከሽንት ፊኛ ጫፍ እጢ ጋር ከተያያዙ ምልክቶች አንዱ ነው ብለው ያስባሉ?	1. አዎ	2. አላስብም
212	ሽንት ለመሸናት መቸገር የሽንት ፊኛ ጫፍ እጢ ምልክቶች አንዱ ነው ብለው ያስባሉ?	1. አዎ	2. አላስብም
213	የሽንት ፊኛ ጫፍ እጢ ጋር ተያያዥነት ካላቸው ምልክቶች የወገብ ህመም አንዱ ነው ብለው ያስባሉ?	1. አዎ	2. አላስብም
214	የዳሌ አጥንት ህመም ከሽንት ፊኛ ጫፍ እጢ ምልክቶች አንዱ ነው ብለው ያስባሉ?	1. አዎ	2. አላስብም
215	በሽንት ውስጥ ደም መታየት ከሽንት ፊኛ ጫፍ እጢ ጋር ተያያዥነት ካላቸው ምልክቶች አንዱ ነው ብለው ያስባሉ?	1. አዎ	2. አላስብም



216	በግብረ ስጋ ግኑኝነት ግዜ ከብልት ውስጥ የዘር ፈሳሽ ሲፈስ የሚሰማ ህመም ከሽንት ፊኛ ጫፍ እጢ ጋር ግኑኝነት ያለው ምልክት ነው ብለው ያስባሉ?	1. አዎ	2. አላስብም
-----	---	-------	----------

**IV. ስለ ሽንት ፊኛ ጫፍ እጢ ምርመራ የግንዛቤ ጥያቄዎች**

217	ለሽንት ፊኛ ጫፍ እጢ ቅድመ ምርመራ በማድረግ የህመሙን መቅረፍ እድል ይጨምራል ብለው ያስባሉ	1. አዎ	2. አላስብም
-----	--	-------	----------

218	የሽንት ፊኛ ጫፍ ችግር ላለባቸው ታካሚዎች በፊንጢጣ በኩል ስለሚደረግ ምርመራ አይነት ያውቃሉ?	1. አዎ	2. አላውቅም
-----	---	-------	----------

219	ለ 218ኛው ጥያቄ መልስዎት አዎ ከሆነ እጤን መረጃ ከየት ሊሰጡት ቻሉ?	1. ከቴሌቭዥን 2. ከራዲዮ 3. ከመገናኛ ብዙሃን 4. ከህክምና ባለሙያ 5. ከጓደኛ 6. ሌላ ካለ (ይጥቀሱ)-----
-----	---	---

220	የሽንት ፊኛ ጫፍ ችግር ላለባቸው ታካሚዎች የደም ውስጥ የፕሮቴን (PSA) መጠን ምርመራ እንደሚደረግላቸው ያውቃሉ?	1. አዎ	2. አላውቅም
-----	--	-------	----------

221	ለ 220ኛው ጥያቄ መልስዎት አዎ ከሆነ እጤን መረጃ ከየት ሊሰጡት ቻሉ?	1. ከቴሌቭዥን 2. ከራዲዮ 3. ከመገናኛ ብዙሃን 4. ከህክምና ባለሙያ 5. ከጓደኛ 6. ሌላ ካለ (ይጥቀሱ) -----
-----	---	--

**V. የሽንት ፊኛ ጫፍ እጢን የመከላከያ እርምጃዎችን የተመለከተ የግንዛቤ ጥያቄዎች**

የምታውቀውን ማንኛውንም የሽንት ፊኛ ጫፍ እጢን መከላከያ ዘዴ መለየት; ብዙ መልሶች ይፈቀዳሉ

N <sup>o</sup>	መጠይቅ	1. አዎ	2. አላውቅም
222	የሽንት ፊኛ ጫፍ እጢ ሊከላከሉት የሚችል በሽታ ነው?		

223	ሲጋራ ማጨስን በማቆም የሽንት ፊኛ ጫፍ እጢን መከላከል ይችላል?		
224	የአልኮሆል መጠጣትን በማቆም የሽንት ፊኛ ጫፍ እጢን መከላከል ይችላል?		
225	ቅድመ ምርመራ በጤና ተቋማት ማድረግ የሽንት ፊኛ ጫፍ እጢን መከላከል ይችላል?		
226	መደበኛ የአካል ብቃት እንቅስቃሴ ማከናወን (የእግር ጉዞ፣ ሩጫ) የሽንት ፊኛ ጫፍ እጢን መከላከል ይችላል?		
227	ስብ(ቅባት) የበዘበትን ምግብ መቀነስ የሽንት ፊኛ ጫፍ እጢን መከላከል ይችላል?		
228	ከብዙ ሰዎች ጋር የግብረ ስጋ ጉኝነት አለማድረግ የሽንት ፊኛ ጫፍ እጢን መከላከል ይችላል?		
229	ከጤና ባለሙያዎች ጋር ስለ ጤናዎ መነጋገር የሽንት ፊኛ ጫፍ እጢን መከላከል ይችላል?		
230	በቂ ፍራፍሬዎችን እና አትክልቶችን መመገብ / መጠቀም የሽንት ፊኛ ጫፍ እጢን መከላከል ይችላል?		

# APPENDIX -E: LEAFLET OF AWARENESS

## የሽንት ፊኛ ጫፍ እጢ

የሽንት ፊኛ ጫፍ ከሽንት ፊኛ መግቢያ እና ላይ የሚገኝ ተባብሮ ሲሆን፤ እርሱም ወንዶች ብቻ ላይ የሚገኝ የሰውነት ክፍል ነው። በወንድ የዘር ፍሬ ውስጥ የሚገኙትን የወንድ የዘር ሀሞላትን የሚመግብ እና የሚከላከል ( ፈሳሽ ያመነጫል ፣ እንዲሁም የፕሮስቲት ተግባር እና እድገት ቁጥጥር የሚደረገው androgen (testosterone) ስሙስል ስሚታወቀው ሆኖ ነው ። የሽንት ፊኛ ጫፍ እጢ የሽንት ፊኛ ጫፍ መታወክ በሽታ ነው ፣ ወይም የበሽታ ምልክት ነው ። የሽንት ፊኛ ጫፍ እጢ በወንዶች ላይ በጣም የተለመደ የካንሰር ዓይነት ነው ፣ በዓለም ዙሪያ በወንዶች ላይ እምስቱኛውን የካንሰር ሞት መጠን ከፍ ያደረገው ነው። በሀገራችንም ከቅርብ ግዜ ወዲህ የተማረውንና እምራች ጋይል የሆኑትን እያጠቃ የሚገኝ የካንሰር አይነት ሲሆን ይህ በራሪ ጽሑፍም የተዘጋጀውም ግንዛቤን ለመጠናቀቅ ነው።

## የሽንት ፊኛ ጫፍ እጢ የሚያጋልጡ ምክንያቶች

የእድሜ መጨመር ፣ በዘር፣ በቤተሰብ መካከል ተጋላጭነት መኖር፣ ሲጋራ ማጨስ ፣ አልኮል መጠጣት ፣ መደበኛ የአካል ብቃት እንቅስቃሴ አለማድረግ፣ ከመጠን ያለፈ ክብደትንና አታክልትና ፍራፍሬ በበቂ ሁኔታ አለመመገብ፣ የተደጋገመ / ቀድሞ የነበረ/ የሽንት ፊኛ ጫፍ ህመም ና ልቅ የሆነ ግብረ ስጋ ገኘነትን ማከናወን።

## የሽንት ፊኛ ጫፍ እጢ ምልክቶች

ቶሎ ቶሎ (በማጣደፍ) ሽንት መሽፍት፣ ሽንት ለመሽፍት መቸገር፣ የወገብና የዳሌ አጥንት ህመም፣ ስንፈተ ወሲብና በግብረ ስጋ ግኑኝነት ግዜ ከብልቅ ውስጥ የዘር ፈሳሽ ሲፈሰ የሚሰማ ህመም።

## የሽንት ፊኛ ጫፍ እጢን የመከላከያ እርምጃዎችን

የሽንት ፊኛ ጫፍ እጢ ሊከላከሉት የሚችል በሽታ ነው። መከላከል የሚቻለበት መንገድም። ሲጋራ አለማጨስ፣ አልኮል አለመጠጣት፣ ምርመራ በጤና ተቋማት ማድረግ፣ መደበኛ የአካል ብቃት እንቅስቃሴ ማከናወን (የእግር ጉዞ ፣ ሩጫ) ፣ ስብ(ቅባት) የበዘበትን ምግብ መቀነስ፣ ከብዙ ሰዎች ጋር የግብረ ስጋ ግኑኝነት አለማድረግ፣ ከጤና ባለሙያዎች ጋር ስለ ጤናዎ መነጋገር፣ በቂ ፍራፍሬዎችን እና አትክልቶችን መመገብ/ መጠቀም።

**ልብ ይበሉ።** ከላይ የተዘረዘሩት እጋልጭ ምክንያቶች ካሉና በጤናዎ ላይ የተጠቀሱትን ምልክቶች ከተመለከቱ አቅረቢያዎ ወደሚገኝ ጠና ተቋም በመቅረብ በጤና ባለሙያ ሊታይ እንባል። በጋራ ካንሰርን በመወጋት ጤና ለሁሉም ሁሉም ለጤና እንተባበር።



## Document Information

<b>Analyzed document</b>	Tilaye@ (2021) Thesis .docx (D105817090)
<b>Submitted</b>	5/21/2021 7:28:00 AM
<b>Submitted by</b>	Hussen Mekonnen
<b>Submitter email</b>	hussen.mekonnen@aau.edu.et
<b>Similarity</b>	6%
<b>Analysis address</b>	hussen.mekonnen.aauni@analysis.urkund.com

## Sources included in the report

**W** URL: <http://213.55.95.56/bitstream/handle/123456789/21383/kaleb%20kan>  
Fetched: 5/19/2021 8:38:33 AM

**W** URL: <http://etd.aau.edu.et/bitstream/handle/123456789/12328/Selamawit%20>  
Fetched: 1/10/2021 9:43:24 PM

**W** URL: <http://etd.aau.edu.et/bitstream/handle/123456789/24042/Danile%20>  
Fetched: 5/14/2021 10:46:49 AM

**W** URL: <http://etd.aau.edu.et/bitstream/handle/123456789/4001/Almaz%20H>  
Fetched: 5/7/2021 11:50:23 AM

**W** URL: <http://213.55.95.56/bitstream/handle/123456789/13383/ABAY%20WC>  
Fetched: 5/19/2021 8:38:36 AM

**W** URL: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2776337/>  
Fetched: 5/21/2021 7:28:00 AM

**W** URL: <http://etd.aau.edu.et/bitstream/handle/123456789/14549/Merkeb%20>  
Fetched: 1/14/2021 5:10:29 AM

**W** URL: <https://core.ac.uk/download/pdf/199938065.pdf>  
Fetched: 6/27/2020 8:52:22 AM

**W** URL: <http://etd.aau.edu.et/bitstream/handle/123456789/21402/Olantu%20>  
Fetched: 11/25/2020 9:29:20 AM

**W** URL: <http://etd.aau.edu.et/bitstream/handle/123456789/9041/Tigist%20Be>  
Fetched: 2/28/2021 5:32:03 PM

**W** URL: <http://etd.aau.edu.et/bitstream/handle/123456789/3655/Alemayehu%20>